



# 260 Companies: Longevity in UK

1. 2Gether
2. Abcodia
3. Abingdon Health
4. Abzena plc
5. Achilles Therapeutics
6. Adaptimmune
7. Aerobit Health
8. AgeWage
9. AHA Health
10. Akari Therapeutics
11. Alcove
12. Ally Smart Care
13. AlphaBiomics
14. Altacor
15. AMO Pharma
16. AMSBIO
17. ANGLE plc
18. Aparito
19. Arcis Biotechnology
20. Arete Medical Technologies
21. Argonaut Therapeutics
22. Aridhia Informatics
23. Arrayjet
24. ARUK-Arthritis Research UK
25. Astex
26. Atelerix
27. Atlas Biomed Group
28. Auriens
29. Autism Biotech
30. Autolus Limited
31. Avalon AI
32. AvantiCell Science
33. Aventyn
34. Avita Medical
35. Babylon health
36. Basingstoke and Alton Rehabilitation Charity Ltd
37. Beacon Inclusive
38. Behavioural Insights Team
39. Benevolent AI
40. Biogelx
41. Bioline
42. BioMoti
43. Birdie
44. Blue Maestro
45. BrainWaveBank
46. Brand Biology
47. Breezie
48. BuddyHub
49. C4X Discovery
50. Cambridge Biolabs
51. Cambridge Oncometrix
52. CareRooms
53. CareZapp
54. CaringMate
55. Celixir
56. Cell Guidance Systems
57. Cell Medica
58. Cell and Gene Therapy Catapult
59. CellAge
60. CellCap Technologies
61. CellCentric
62. Celleron Therapeutics
63. Cellesce
64. Cera
65. Choice Care Group
66. Chronos Therapeutics
67. Cobra Biologics
68. Cognition Kit
69. Collagen Solutions
70. Community Lincs
71. Community Men2Men
72. Complete Care
73. Connector CIC
74. Consequential Robotics
75. Consulting on Advanced Biologicals
76. Cre8 Care
77. CRISPR Therapeutics
78. Ctrl Group
79. Curam
80. Cytos
81. Definigen
82. Destiny Pharma
83. Diagnostic Healthcare
84. Digital Care Planning
85. Docandu
86. DoctorLink
87. Eagle Genomics
88. Earlham Institute
89. Echo
90. Echo Care

|      |                               |      |                                  |      |                        |
|------|-------------------------------|------|----------------------------------|------|------------------------|
| 91.  | Edinburgh Molecular Imaging   | 121. | IDIS                             | 151. | Minatx                 |
| 92.  | Elpis BioMed                  | 122. | Immune Targeting Systems         | 152. | Mission Therapeutics   |
| 93.  | Engitix                       | 123. | ImmuPharma                       | 153. | Molecular Vision       |
| 94.  | EnteroBiotix                  | 124. | InCommon Living                  | 154. | Mologic                |
| 95.  | Epistem Holdings              | 125. | Ingenza                          | 155. | Monica Healthcare      |
| 96.  | eScent                        | 126. | IntelliHep                       | 156. | Morgan Ash.            |
| 97.  | eTherapeutics                 | 127. | Invizius                         | 157. | Move It or Lose It     |
| 98.  | Evox Therapeutics             | 128. | Jellagen                         | 158. | Mursla                 |
| 99.  | FitnessGenes                  | 129. | Kafoodle                         | 159. | MyCareMatters          |
| 100. | Freeline Therapeutics         | 130. | Kalgera                          | 160. | MySense                |
| 101. | From Generation to Generation | 131. | Kareinn                          | 161. | Nanokick Technologies  |
| 102. | Fuss Free Phones              | 132. | Kemuri                           | 162. | NanoTherics            |
| 103. | Genedrive Plc                 | 133. | Kintell LTD                      | 163. | Nell Natural Elements  |
| 104. | GeneFirst                     | 134. | Kraydel                          | 164. | NeoPhore               |
| 105. | Give & Take Care              | 135. | Lab21                            | 165. | NeRRe Therapeutics     |
| 106. | Gluecks Bewegungsmusik        | 136. | Leicestershire Partnership Trust | 166. | Newcells Biotech       |
| 107. | Gracewell Healthcare          | 137. | Levicept                         | 167. | Nightstar Therapeutics |
| 108. | Graphnet Health               | 138. | Life's Back-Up                   | 168. | Nuclera Nucleics       |
| 109. | Guardian Angel                | 139. | Lifeline 24                      | 169. | Open Bionics           |
| 110. | Guideposts Trust              | 140. | LifeStage                        | 170. | Open Hand Project      |
| 111. | GW Pharmaceuticals            | 141. | LIFNano Therapeutics             | 171. | Open Inclusion         |
| 112. | Healx                         | 142. | LifT BioSciences                 | 172. | Optellum               |
| 113. | HEC Montreal                  | 143. | Lydian stream                    | 173. | Optibiotix Health      |
| 114. | Hello Daisy                   | 144. | Map a Nurse                      | 174. | Orca Pharmaceuticals   |
| 115. | Heptares Therapeutics         | 145. | Memory Tracks                    | 175. | Orchard Therapeutics   |
| 116. | Heterogeneous                 | 146. | Memrica                          | 176. | Orthogem               |
| 117. | Horizon Discovery             | 147. | Methuselah Health                | 177. | Orthox                 |
| 118. | Howz                          | 148. | Michelson Diagnostics            | 178. | Osler Diagnostics      |
| 119. | hVIVO                         | 149. | Micrima                          | 179. | Owlett                 |
| 120. | iamYiam                       | 150. | miiCARE                          | 180. | Oxford Biodynamics     |

|      |                                     |      |                                  |      |                           |
|------|-------------------------------------|------|----------------------------------|------|---------------------------|
| 181. | Oxford BioMedica                    | 211. | ReMe                             | 241. | Tissue Regenix            |
| 182. | Oxford Gene Technology              | 212. | Renalytix AI                     | 242. | Toucan                    |
| 183. | Oxford Genetics                     | 213. | ReNeuron Group                   | 243. | Touch Bionics             |
| 184. | Oxford Immunotec                    | 214. | Rexgenero                        | 244. | Tunstall Healthcare Group |
| 185. | Oxstem                              | 215. | Right Angle                      | 245. | UGO                       |
| 186. | Patients Know Best                  | 216. | Rogue Resolutions                | 246. | Ukactive                  |
| 187. | Perfectus Biomed                    | 217. | Roslin Cells                     | 247. | Vaccitech                 |
| 188. | PfT Planning                        | 218. | RowAnalytics Ltd                 | 248. | ValiRX                    |
| 189. | Phico Therapeutics                  | 219. | Sage Therapeutics                | 249. | Verona Pharma             |
| 190. | Phoqus Pharmaceuticals              | 220. | Scancell                         | 250. | Vertex Pharmaceuticals    |
| 191. | PhoreMost                           | 221. | Seniors Rock                     | 251. | Vida                      |
| 192. | Physiomics                          | 222. | Sensio Air                       | 252. | Videregen                 |
| 193. | Plan Snap                           | 223. | Sernova                          | 253. | VirionHealth              |
| 194. | Plasticell                          | 224. | Service Robotics Ltd             | 254. | Virttu Biologics          |
| 195. | PneumaCare                          | 225. | Shift8 Limited                   | 255. | Walk with Path            |
| 196. | Pocket Clinic                       | 226. | Sibelius                         | 256. | Wellics                   |
| 197. | Precision Dental Laboratories Group | 227. | Sistemic                         | 257. | WideCells Group           |
| 198. | Precision Medicines                 | 228. | SkyePharma (Acquired by Vectura) | 258. | Wise-Up                   |
| 199. | Premaitha Health                    | 229. | SmartTarget                      | 259. | Xenetic Biosciences       |
| 200. | Prestige Nursing                    | 230. | Society for Later Life Advisers  | 260. | Zio Health                |
| 201. | Priestman Goode                     | 231. | Solentim                         |      |                           |
| 202. | Proteome Sciences                   | 232. | Sphere Fluidics                  |      |                           |
| 203. | Proximagen                          | 233. | StoriiCare                       |      |                           |
| 204. | Psioxus Therapeutics                | 234. | Suisse Life Science Group plc    |      |                           |
| 205. | Pzizz - Sleep, Nap, Focus           | 235. | SwabTech                         |      |                           |
| 206. | QuantuMDx Group                     | 236. | Swift Molecular Diagnostics      |      |                           |
| 207. | Quethera                            | 237. | Synpromics Ltd                   |      |                           |
| 208. | Reassura                            | 238. | TC BioPharm                      |      |                           |
| 209. | Regenerys                           | 239. | The Chatty Café Scheme           |      |                           |
| 210. | Remarkable Lives                    | 240. | Theolytics                       |      |                           |

# 2Gether



2Gether is a platform-based service that enables connection and helps reduce loneliness among the elderly population by creating a musical-social experience. Founded in 2016 by Roy Tal, based in Israel, a social start-up that strives to improve the well-being for the elderly population.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://2gether.fun">2gether.fun</a> |
| Number of Employees:  | 5-10  |
| Location:             | Undisclosed                                   |
| Founded in:           | Undisclosed                                   |
| Sector:               | Preventative Medicine                         |
| Total Funding Amount: | Undisclosed                                   |

# Abcodia



Abcodia is a clinical stage company engaged in the commercial development of novel, validated tests for the early detection of cancer. The company's first product is the ROCA test for the early detection of ovarian cancer, and it is also expanding its pipeline of early detection technologies for lung, colorectal and pancreatic cancer. Abcodia's offerings are based on expertise in measuring and modeling dynamic changes over time of serum-based biomarkers before cancer is clinically diagnosed.

It maintains exclusive commercial access to a biobank of 5 million samples donated from 200,000 individuals over a 10-year period and has its own CLIA-certified laboratory. Abcodia holds strategic collaborations with leading global organizations including Cancer Research UK, University College London and other academic and industry partners.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://abcodia.com">abcodia.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | 2010   |
| Based in:             | London                                       |
| Sector:               | Regenerative medicine                        |
| Total Funding Amount: | \$10.2M                                      |

# Abingdon Health



Abingdon Health is an innovative technology-led company focused on providing rapid and near-patient medical diagnostic testing solutions.

We are building an innovative technology-led company focused on providing rapid and near-patient medical diagnostic testing solutions.

We are developing, manufacturing and selling products and systems that support the migration of testing from the laboratory closer to the patient with the intention of improving both clinical and economic healthcare outcomes. Our initial clinical focus is on developing a range of rapid testing products in the areas of hematology oncology, specifically B-cell dyscrasias.

We will use our expertise in immunodiagnosics, plastic electronics, hardware and software, to develop the next generation of testing systems that meet the needs of our customers. Our current platform development is looking to provide customers with a multiplexed, portable, cost-effective and connected rapid testing solution.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://abingdonhealth.com">abingdonhealth.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | 2008   |
| Based in:             | York   |
| Sector:               | Personalized medicine                                      |
| Total Funding Amount: | £12.6M   |

# Abzena plc



Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.

The term “Abzena inside” is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on “Abzena inside” products.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://abzena.com">abzena.com</a> |
| Number of Employees:  | 101-250                                    |
| Founded in:           | Cambridge                                  |
| Based in:             | 2002                                       |
| Sector:               | Personalized medicine                      |
| Total Funding Amount: | £40M                                       |



# Achilles Therapeutics



Achilles Therapeutics' aims to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells. The therapies will target truncal (also known as clonal) tumour neo-antigens, unique flags to the immune system present on the surface of every cancer cell. These truncal neo-antigens are created early in the cancer's evolution and present on all cancer cells in an individual patient's tumour but not on healthy cells, so could allow scientists to target and destroy tumours without harming healthy tissues.

The company is headquartered in London, UK and was launched in May 2016.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://achillestx.com">achillestx.com</a> |
| Number of Employees:  | Undisclosed  |
| Founded in:           | Stevenage  |
| Based in:             | 2016   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | £13.2M   |

# Adaptimmune



Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses.

The company was incorporated in 2007 and is based in Abingdon, United Kingdom.

Stock Symbol: NASDAQ:ADA

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://adaptimmune.com">adaptimmune.com</a> |
| Number of Employees:  | 51-100   |
| Founded in:           | Oxton  |
| Based in:             | 2008   |
| Sector:               | Preventive medicine                                  |
| Total Funding Amount: | \$249.5M   |

# Aerobit Health



With 2/3rds of asthma deaths being preventable and the majority of severe asthma symptoms able to be significantly reduced, Aerobit sees creating tools to simplify the adherence and tracking of treatment as the biggest opportunity for improvement in the marketplace. Adherence with doctor-recommended treatment programs has long been recognized as a leading cause of unachieved outcomes. They see the upcoming revolution in digital health care as the turning point in delivering positive outcomes for UK asthma sufferers. They know that controlled asthma imposes far less of an economic burden than non-controlled asthma. Their strategies are focused towards improving adherence to doctor-recommended treatments.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://aerobithealth.com">aerobithealth.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | Manchester   |
| Based in:             | Undisclosed  |
| Sector:               | Preventive medicine                                      |
| Total Funding Amount: | Undisclosed  |

# AgeWage



AgeWage affords older people the chance to get their pension pots assessed for value for money. It provides a score for each pot it finds which allows the vulnerable to take informed decision decisions on how to manage their investments and spend their savings in an organised way.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://agewage.com">agewage.com</a> |
| Number of Employees:  | 5-10   |
| Location:             | London                                       |
| Founded in:           | Undisclosed                                  |
| Sector:               | AgeTech                                      |
| Total Funding Amount: | Undisclosed                                  |

# AHA Health



AHA goes beyond the ability to predict Health Risks and provides the ability to do something about it. Amazing technology for Patient Care that improves quality of care and drive the cost of care down.

- AHA Health helps you to gather personal health information whether you are at home or work through questionnaires, medical devices, wearables and data from healthcare providers into a Single Personal Health Record.
- AHA Health's health risk monitoring engine can analyse trends and pick up abnormalities in near real time based on clinically validated algorithms as well as personalised monitoring parameters set by the Doctors.
- AHA Health's Intervention support system can alert you, your Carer and Doctor of any issues and empower them to provide proactive healthcare. AHA Health helps doctors to diagnose diseases before it's too late.
- AHA Health's machine learning platform can identify Patterns and clusters to create unique Digital health therapeutics or algorithmic models that will change the way health care is provided in future. It helps Doctors provide good quality of care.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://ahahealth.io">ahahealth.io</a> |
| Number of Employees:  | Undisclosed                                    |
| Founded in:           | Undisclosed                                    |
| Based in:             | Undisclosed                                    |
| Sector:               | Personalized medicine                          |
| Total Funding Amount: | Undisclosed                                    |

# Akari Therapeutics


 The logo for Akari Therapeutics, featuring the word "AKARI" in a large, red, serif font, with "THERAPEUTICS" in a smaller, red, sans-serif font below it. The logo is enclosed in a dashed blue rectangular border.

Akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. Akari's lead drug, Coversin is a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b-9 (also known as the membrane attack complex or MAC). C5 inhibition is growing in importance in a range of rare autoimmune diseases related to dysregulation of the complement component of the immune system, including paroxysmal nocturnal hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS), and Guillain Barré syndrome (GBS).

Stock Symbol NASDAQ:AKTX

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://akaritx.com">akaritx.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | London                                       |
| Based in:             | 2005   |
| Sector:               | Preventive medicine                          |
| Total Funding Amount: | \$87.5M                                      |

# Alcove



250

Alcove was formed in 2014 with the aim to pioneer independent living for older and disabled adults. Revolutionising care and support by leveraging the power of today's consumer technology to empower users and provide caregivers with better tools. Mostly, their customers just get on with their lives as normal - they don't have to do anything differently. If they do, they have locked down all their devices so they are super simple to use.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://youralcove.com">youralcove.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | London   |
| Based in:             | 2014   |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |

# Ally Smart Care



Ally Smart Care can help with early detection and treatment of falls, chest infections, UTIs and depression.

Ally is a single plug-in device that harnesses the power of passive sound monitoring to keep track of the health of an elderly loved one. Worrying adult caregivers are alerted via a mobile app to any key changes in health.

It uses passive sound observation to provide rich data about physical & mental states with a simple user experience that is easy for both families and seniors. Their smart algorithms piece together individual events over time including general activity, coughing, sleep patterns and mood to predict potential health concerns like flu or depression.

Additional product benefits include simple messaging, reminders and calls.

|                       |                                      |
|-----------------------|--------------------------------------|
| Web site:             | <a href="http://ally.is">ally.is</a> |
| Number of Employees:  | Undisclosed                          |
| Founded in:           | Undisclosed                          |
| Based in:             | Undisclosed                          |
| Sector:               | Preventive medicine                  |
| Total Funding Amount: | Undisclosed                          |



# AlphaBiomics

AlphaBiomics

AlphaBiomics was founded by prominent scientists and entrepreneurs from industry and Academia. For the past several years, our team has been committed to investigating the role of the microbiome in health and disease. More recently, we have expanded our interest to the emerging field of pharmacomicrobiomics. Given the highly variable clinical response to drugs, we recognized a need for better and personalized predictive patient care and an opportunity to leverage the microbiome to deliver safer and more efficacious drug therapies. We started AlphaBiomics with the mission to develop microbiome-based precision medicine solutions that will predict drug response and improve drug therapy.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://alphabiomics.com">alphabiomics.com</a> |
| Number of Employees:  | Undisclosed  |
| Founded in:           | London   |
| Based in:             | 2018   |
| Sector:               | Personalized medicine                                  |
| Total Funding Amount: | €100K  |

# Altacor (Acquired by Esperante Ventures)



Altacor develops and brings to market specialist ophthalmic products designed for the needs of both ophthalmologists and patients.

From its headquarters in Cambridge UK, Altacor brings together skills in drug development with in-depth market knowledge and an understanding of the European regulatory environment, to create a portfolio of high quality, differentiated prescription medicines that set new standards in the sector.

Altacor's pipeline includes products for dry-eye, glaucoma, glaucoma surgery and ocular surgery.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://altacor-pharma.com">altacor-pharma.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | Cambridge  |
| Based in:             | 2005   |
| Sector:               | Regenerative medicine                                      |
| Total Funding Amount: | £1.9M  |

# AMO Pharma



AMO Pharma is dedicated to making a positive difference for people affected by serious and debilitating diseases, particularly rare or orphan diseases. To do this, we first work to understand the areas of unmet need and the experience of living with any disease we are targeting. We then use our extensive experience in drug development to identify and advance therapies that can significantly improve clinical outcomes while offering the strongest opportunities for approval. With drugs designed to reduce disease burden, slow disease progression or reduce many or all symptoms of a disease, our goal is to give patients an opportunity for improved health and quality of life. Our passion for drug development is strengthened and inspired by many personal connections to the rare disease community held by members of our senior team.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://amo-pharma.com">amo-pharma.com</a> |
| Number of Employees:  | Undisclosed  |
| Founded in:           | Wonersh  |
| Based in:             | Undisclosed  |
| Sector:               | Regenerative medicine                              |
| Total Funding Amount: | \$25M  |

# AMSBIO

The logo for AMSBIO, featuring the word "amsbio" in a white, lowercase, sans-serif font on a dark blue rectangular background.

255

Founded in 1987, AMSBIO (AMS Biotechnology) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology products and services for research and development in the medical, nutrition, cosmetics and energy industries. The AMSBIO range includes specialist antibodies, peptides and recombinant proteins. In addition, the company is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as experts in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance screening outcomes and eventual prognosis. With a range of molecular detection reagents, and a significant Biorepository the company can also provide tissue DNA, RNA, protein and microarray products. Key research areas for these products include: Oncology, Regenerative Medicine, Environmental Analysis, Cytotoxicity Screening, Glycomics and Stem Cell Biology.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://www.amsbio.com">amsbio.com</a> |
| Number of Employees:  | 11-50   |
| Founded in:           | Abingdon  |
| Based in:             | 1987  |
| Sector:               | Personalized medicine                           |
| Total Funding Amount: | Undisclosed                                     |

# ANGLE plc



ANGLE plc is a commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and foetal health. ANGLE also owns a successful specialist technology consultancy and a major investment in a business with a unique computer graphics technology platform. ANGLE was founded by Andrew Newland in 1994 to bridge a gap between research and the market. ANGLE's business model is to set up, own and operate technology companies to commercialise world-class research. The business has matured so that it now focuses on its established 90%+ owned businesses with unique high value patent protected medical technologies addressing multi-billion dollar markets. ANGLE's lead product is the Parsortix cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE has launched a product for the research market and is aiming to secure CE Mark regulatory approval for the clinical market in 2013 with FDA approval in 2014.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://angleplc.com">angleplc.com</a> |
| Number of Employees:  | 51-100   |
| Founded in:           | Guildford                                      |
| Based in:             | 1994   |
| Sector:               | Personalized medicine                          |
| Total Funding Amount: | \$250K   |

Aparito provides wearable devices and disease-specific mobile apps to provide remote patient monitoring outside of the hospital environment.

This delivers meaningful, relevant, and real-time data between patients and clinicians in a way that actively supports and enhances diagnosis, treatment and drug development. By embracing digital health technology.

They connect patients to doctors - and to parents/ carers – via remote monitoring to support better patient outcomes, improve understanding of disease, and clinical trial outcomes.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://aparito.com">aparito.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | London                                       |
| Based in:             | 2015   |
| Sector:               | Personalized medicine                        |
| Total Funding Amount: | £15K   |



# Arcis Biotechnology

Arcis Biotechnology is focused on providing fast and convenient nucleic acid sample prep solutions. Obtaining genetic material from biological samples is a critical step which is often a time consuming and inefficient process. In less than 3 minutes with no prior sample preparation the Arcis DNA Prep range of products allow users to quickly and conveniently go from cellular material to downstream nucleic acid investigation without the need for traditional isolation or purification. The process requires no laboratory equipment and requires as little as 30µl of blood as a starting material. Arcis DNA products can be used on many different samples containing DNA including whole blood, plasma, urine, buccal swabs, and hair follicles.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://arcisbio.com">arcisbio.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | Warrington                                     |
| Based in:             | 2009   |
| Sector:               | Personalized medicine                          |
| Total Funding Amount: | £6.6M  |

# Arete Medical Technologies



Arete Medical Technologies is a startup creating medical devices and software for precision approaches to chronic diseases, starting with asthma and COPD.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://aretemedtech.com">aretemedtech.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | Cambridge  |
| Based in:             | 2017   |
| Sector:               | Personalized medicine                                  |
| Total Funding Amount: | Undisclosed  |



# Argonaut Therapeutics



Argonaut Therapeutics is a precision therapeutics company that was established to develop epigenetically-acting drugs which target abnormal arginine methylation in cancer. The company was founded on pioneering research from the University of Oxford, UK. Argonaut strives to develop a new class of precision cancer medicines which target the enzymes responsible for abnormal arginine methylation in cancer.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://argonauttherapeutics.co.uk">argonauttherapeutics.co.uk</a> |
| Number of Employees:  | Undisclosed  |
| Founded in:           | Oxford   |
| Based in:             | Undisclosed  |
| Sector:               | Personalized medicine  |
| Total Funding Amount: | Undisclosed  |

# Aridhia Informatics



Aridhia provides world leading biomedical informatics and analytic solutions to support stratified medicine and translational research, which will enhance understanding, diagnosis, prevention and treatment of chronic diseases. Aridhia believes that the integration and application of patient, clinical and genomic data represents a powerful opportunity to support clinical care across healthcare sectors, provide patients with the ability to take a more active role in their own care and provide information at a population level about disease trends, risk factors, impact of treatment and informed public health programmes. Working in close collaboration with experts in a clinical faculty model, Aridhia's multidisciplinary team provides a unique combination of expertise to address one of the world's most pressing health problems.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://aridhia.com">aridhia.com</a> |
| Number of Employees:  | 51-100                                       |
| Founded in:           | Edinburgh                                    |
| Based in:             | 2008   |
| Sector:               | Personalized medicine                        |
| Total Funding Amount: | £1.1M  |

# Arrayjet



Arrayjet Ltd was established in 2000 with private equity from the Archangel Investors Ltd and the Scottish Government. The company developed and patented an inkjet technology to print biological samples onto solid substrates to create screening tools called microarrays. Arrayjet have been at the forefront of this field since commercialisation in 2006 and have a broad customer-base across 27 countries. Arrayjet has strong brand presence and a respected reputation for high-throughput inkjet printing systems, dependable customer service and assay development expertise. Arrayjet was originally an instrument business but began developing a contract service arm in 2010. In 2011 we launched Arrayjet Advance™ to offer a range of outsourced services for assay development, printing and contract manufacturing. In 2016 we added Arrayjet Expertise™ to offer services for consultancy, project management and training.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://arrayjet.co.uk">arrayjet.co.uk</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | Edinburgh  |
| Based in:             | 2000   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | £650K  |

# Arthritis Research UK



Everything we do is driven by knowledge to positively impact on what matters to people with arthritis.

Our long term commitment is to:

- **prevent** the onset of arthritis
- develop a **cure** for arthritis
- **transform** the lives of those with arthritis.

Too many people live with the pain, isolation and fatigue arthritis causes. This has to stop.

Arthritis Research UK has merged with Arthritis Care so that we can address this huge unmet need and do more for, and with, people with arthritis.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://arthritisresearchuk.org">arthritisresearchuk.org</a> |
| Number of Employees:  | 101-250  |
| Founded in:           | Undisclosed  |
| Based in:             | Undisclosed  |
| Sector:               | Personalized medicine  |
| Total Funding Amount: | Undisclosed  |

## Astex (Acquired by SuperGen)



Astex is a UK-based biotechnology company that discovers and develops novel small molecule therapeutics. Using its pioneering fragment-based drug discovery platform, Pyramida, Astex has built a pipeline of molecularly-targeted oncology drugs, of which three are currently being tested in clinical trials with others in discovery and preclinical development.

In addition to its proprietary research programs, Astex™'s productivity in lead discovery has been endorsed through numerous partnerships with major pharmaceutical companies, including AstraZeneca, GlaxoSmithKline, Johnson & Johnson and Novartis.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://astx.com">astx.com</a> |
| Number of Employees:  | 51-100                                 |
| Founded in:           | Cambridge                              |
| Based in:             | 1999                                   |
| Sector:               | Personalized medicine                  |
| Total Funding Amount: | Undisclosed                            |

# Atelerix



Atelerix has a transformative technology for the storage and transport of viable cells at room temperature, overcoming the barriers and limitations presented by the current need for cryo-shipping. We do this using our patented process of encapsulating the cells in a natural hydrogel for safe shipment and storage. The cells can be recovered when needed by the addition of a gentle, cell-friendly buffer. This means: Predictability and reliability in drug discovery models and for cells used as therapies Customers can use cells and assays immediately on arrival No need for cryopreservation, nor need for cytotoxic or animal-derived supplements Cells retain their natural state and are not damaged nor altered.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://atelerix.co.uk">atelerix.co.uk</a> |
| Number of Employees:  | Undisclosed  |
| Founded in:           | Newcastle  |
| Based in:             | 2006   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | £350K  |

# Atlas Biomed Group



Atlas Biomed is a personalised health company, applying the latest genetic technologies to help you navigate towards your potential. To achieve this, Atlas has two tests available in the UK: the Atlas DNA Test and the Atlas Microbiome Test. Both tests feed into the Atlas platform, which allows you to take control of your health through actionable, personalised recommendations.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://atlasbiomed.com">atlasbiomed.com</a> |
| Number of Employees:  | 51-100  |
| Founded in:           | London  |
| Based in:             | 2016  |
| Sector:               | Personalized medicine                                 |
| Total Funding Amount: | Undisclosed   |

# Auriens



Through their beautifully designed properties, world-class services and exceptional healthcare provision, Auriens is dedicated to challenging and subverting the norms of post-retirement (later) living.

They see the advancing years as something to celebrate, and they value agefulness as they do intelligence, attitude, style and sophistication.

At Auriens, their mission is to provide inclusive, comprehensive, centrally located places to live later life to the full. That means the catering is exceptional, the Club and restaurant are stylish places to congregate, and the spa, therapy suites and library are all a joy to linger in. Every requirement, large or small, will be effortlessly satisfied to premium hotel standards and beyond.

Here age is more than just a number – it's a rite of passage to a lifestyle that is as entertaining and enjoyable as it is comfortable.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://auriens.com">auriens.com</a> |
| Number of Employees:  | 2-10   |
| Founded in:           | London                                       |
| Based in:             | Undisclosed                                  |
| Sector:               | AgeTech                                      |
| Total Funding Amount: | Undisclosed                                  |



# Autism Biotech



Autism Biotech Ltd has a ground-breaking product: ASDtect, the world's first diagnostic test for early and reliable detection of autism spectrum disorder (ASD). Based on two fully owned and granted patents for peptide biomarkers for autism, ASDtect targets a huge and untapped market.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://autism-biotech.com">autism-biotech.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | Belfast  |
| Based in:             | 2012   |
| Sector:               | Preventive medicine  |
| Total Funding Amount: | Undisclosed  |

# Autolus Limited



Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors.

Stock Symbol: NASDAQ:AUTL

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://autolus.com">autolus.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | London                                       |
| Based in:             | 2014   |
| Sector:               | Personalized medicine                        |
| Total Funding Amount: | \$181.7M                                     |

# Avalon AI



Avalon AI builds Deep Learning-based Computer Aided Diagnosis tools to facilitate the detection of brain degenerative diseases like Alzheimer's and enable better patient stratification in clinical trials.

We use Machine learning to automatically derive accurate brain features (e.g. the volume of the hippocampus) from brain scans and compare them to a normative population. We also provide handy 2D and 3D visualisations of brain features. This not only saves time to neuroradiologists but also empowers them to make highly accurate reports, by using the latest techniques and findings in neurosciences. We are currently running trials with select clinics in India, Pakistan and Ukraine.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://avalonai.strikingly.com">avalonai.strikingly.com</a> |
| Number of Employees:  | 51-100   |
| Founded in:           | London   |
| Based in:             | 2015   |
| Sector:               | Preventive medicine  |
| Total Funding Amount: | Undisclosed  |

# AvantiCell Science



AvantiCell delivers leading-edge solutions for customers wishing to evaluate bio-activity or bio-safety in a wide-range of test materials; from pharmaceuticals, traditional medicines and natural products to medical devices and nano-structured materials. AvantiCell solutions use advanced cell culture technology based on physiologically-relevant human and animal cells.

AvantiCell supplies a growing range of human primary cell products which are accessible as cell isolates requiring re-culture within the customer's laboratory or in the form of pre-assembled, cryopreserved models. These products make cell-based analysis available to all customers in a plug-and-play format.

AvantiCell also provides its expertise in a range of services ranging from off-the-shelf cell-based assays to specialist cell culture systems customised to meet customers' requirements.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://avanticell.com">avanticell.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | Ayr  |
| Based in:             | 2006   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | €1.3M  |

# Aventyn



Aventyn is an award winning digital health company delivering innovative, standards based secure core to cloud connected clinical information solutions and services to lower health care delivery costs, improve quality and increase patient safety. They provide clinical evidence based solutions for personalized chronic disease management, medical imaging, predictive analytics and risk assessment.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://aventyn.com">aventyn.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | London                                       |
| Based in:             | 2004   |
| Sector:               | Personalized medicine                        |
| Total Funding Amount: | Undisclosed                                  |

# Avita Medical



Avita also has the opportunity to receive up to \$37 million upon execution of specific contract options to further support clinical studies and post-market surveillance that could be potentially required by the FDA to expand the device to the pediatric population, the company said.

Stock Symbol ASX:AVH

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://avitamedical.com">avitamedical.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | Wimbledon  |
| Based in:             | 1999   |
| Sector:               | Regenerative medicine                                  |
| Total Funding Amount: | \$28.6M  |

# Babylon Health



Babylon delivers high quality healthcare via your mobile phone. babylon employs only the very best doctors and provides them with rigorous industry-leading training.

During video visits doctors listen and look carefully to diagnose you or your family member and then write prescriptions or refer you to a specialist if required. Patients rate each visit to ensure quality.

Their mission is the total re-invention of healthcare. They believe technology can be used to give everyone, everywhere, affordable quality medical care. That's why they are creating everyone's own personal health service.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://babylonhealth.com">babylonhealth.com</a> |
| Number of Employees:  | 501-1000   |
| Founded in:           | London   |
| Based in:             | 2013   |
| Sector:               | Preventive medicine                                      |
| Total Funding Amount: | £57M   |

# Basingstoke and Alton Rehabilitation Charity Ltd



Cardiac *Rehab*

Basingstoke & Alton *Cardiac Rehabilitation Charity Ltd*

275

A charity which provides exercise and education for people recovering from cardiac illnesses or operations. For the past nine years we have expanded from this secondary care into primary care, taking on mainly elderly people in need of exercise, particularly those at increased risk of cardiovascular disease.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://cardiac-rehab.co.uk">cardiac-rehab.co.uk</a> |
| Number of Employees:  | 5-10   |
| Location:             | London   |
| Founded in:           | Undisclosed  |
| Sector:               | Preventative Medicine  |
| Total Funding Amount: | Undisclosed  |



# Beacon Inclusive



Beacon Inclusive is a Social Enterprise built upon principles embracing diversity and inclusion for all in the society with a mission to reboot equality by catalyzing Internet of Things technology to facilitate accessibility of Health Services for Vulnerable Groups in Societies (Persons with Disabilities, Refugees and Ageing Population) in society.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://beaconinc.wordpress.com">beaconinc.wordpress.com</a> |
| Number of Employees:  | 5-10   |
| Location:             | Undisclosed  |
| Founded in:           | Undisclosed  |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |

# Behavioural Insights Team



The Behavioural Insights Team (BIT) is a social purpose company whose mission is to apply ideas from the behavioural sciences to real world settings to help, support and enable people to make better decisions for themselves.

The buddying platform would connect isolated individuals with their peers, volunteers, as well as support workers and other healthcare professionals. Primarily it would work by connecting up people via a web-hosted chat platform accessible via an SMS message. Importantly, NETWORKY for Aging will be designed so it can be delivered quickly, at scale and at low cost. We want users to be able to use existing technologies, e.g. SMS, landlines or PCs, rather than needing to, invest in or learn how to use new technology. NETWORKY for Aging will be accessible to people living with disabilities by supporting a range of channels including text and voice recognition. The potential to scale up the platform in order that it is able to connect hundreds of thousands of users could be done immediately and the solution is location agnostic, meaning that we would be able to connect users all over the U.K.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://behaviouralinsights.co.uk">behaviouralinsights.co.uk</a> |
| Number of Employees:  | 11-50  |
| Location:             | London   |
| Founded in:           | Undisclosed  |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |

# BenevolentAI

benevolent.ai

BenevolentAI is one of the largest private AI companies in the world and the global leader in the development and application of AI for scientific innovation.

The company is applying artificial intelligence to develop new medicines for hard to treat diseases. It is the first fully integrated AI company with pharmaceutical discovery and clinical development capabilities. BenevolentAI's advanced technology is disrupting the pharmaceutical industry by lowering costs, decreasing failure rates and increasing the speed at which medicines are delivered to patients.

BenevolentAI currently employs 165 people who work in a unique, cross functional environment that incorporates leading edge data scientists, computer scientists, mathematicians and drug development R&D scientists working side by side. The company is headquartered in London with further offices in New York and Belgium. BenevolentAI's research facility is located in Babraham Science Park, Cambridge (UK).

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://benevolent.ai">benevolent.ai</a> |
| Number of Employees:  | 51-100  |
| Founded in:           | London  |
| Based in:             | 2013  |
| Sector:               | AgeTech   |
| Total Funding Amount: | \$207M  |

# Biogelx



Biogelx is a biomaterials company which designs and supplies peptide hydrogels for cell culture, precisely tuned to the requirements of the cell. These products have applications in fundamental cell research, toxicology/drug development and may ultimately be translated to cell therapy/regenerative medicine. The chemical and physical properties of the hydrogels match the characteristics experienced by cells within tissues, thus enabling the study and manipulation of cells in a realistic 3D environment which is simple, fully defined and tuneable.

The Company's patented hydrogel products are currently selling in the US, Europe and Asia.

The product's unique cell-matching capabilities clearly provide academic users, medical researchers and pharmaceutical companies with a serious alternative to competing 3D cell culture products.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://biogelx.com">biogelx.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | Newhouse                                     |
| Based in:             | 2012   |
| Sector:               | Personalized medicine                        |
| Total Funding Amount: | £790K  |

# Bioline



Founded in 1992 and headquartered in London, UK, Bioline is an evolving international company and our mission is to provide customers with a range of products which are fast and easy to use, guaranteed to work and developed by scientists who understand what our customers are trying to achieve so they can focus on their scientific goals. At Bioline, we constantly strive to improve and to deliver high quality products which are the result of our strong commitment and investment in science. Bioline, wholly owned by Meridian Bioscience Inc. (Nasdaq: VIVO), operates as one multi-cultural global team with strong values.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://bioline.com">bioline.com</a> |
| Number of Employees:  | 251-500                                      |
| Founded in:           | London                                       |
| Based in:             | 1992   |
| Sector:               | Personalized medicine                        |
| Total Funding Amount: | \$62.1M                                      |



One in three of us will get cancer and increases in life expectancy indices will exacerbate this statistic in the future. Most current chemotherapeutics have devastating side effects including hair loss, nausea, weakened immunity and fatigue to name but a few.

BioMoti exists to transform the treatment of cancer patients by doing things differently. BioMoti seeks to transform the treatment of cancer by targeted delivery of therapeutics to the intracellular space of cancer cells; aiming to dramatically increase efficacy whilst reducing side effects.

Oncojans™ are a new class of therapeutic microparticles that target and gain entry to the interior of cancer cells where they slowly release drugs at the point of need whilst sparing healthy tissue. The Oncojan™ platform is compatible with a range of drug classes from small molecule therapeutics to larger biologicals.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://biomoti.com">biomoti.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | London                                       |
| Based in:             | 2009   |
| Sector:               | Preventive medicine                          |
| Total Funding Amount: | £75K   |

# Birdie



Birdie digitalises notes taken by care workers during visits which can be more easily shared between professional carers, other health practitioners and family members, helping to coordinate care and keep an older generation out of care homes or hospital beds.

Five thousand carers have already signed up to use the app on their phones since it was launched in 2017 with 50 families using the app in a pilot.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://birdie.care">birdie.care</a> |
| Number of Employees:  | 11-50  |
| Location:             | London                                       |
| Founded in:           | Undisclosed                                  |
| Sector:               | Personalised Medicine                        |
| Total Funding Amount: | Undisclosed                                  |

# Blue Maestro



Blue Maestro is a leading designer and developer of connected products and solutions, from consumer devices through to their work with NHS England on the next generation of medicine adherence sensors. They have a number of innovative products and solutions under development, several that are patent pending. Meet some of Blue Maestro's management team below.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://bluemaestro.com">bluemaestro.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | Weybridge  |
| Based in:             | 2012   |
| Sector:               | AgeTech  |
| Total Funding Amount: | \$410K   |



# BrainWaveBank



BrainWaveBank's neuroscience platform measures cognitive performance by monitoring brainwave activity while playing fun, engaging mobile games that test specific aspects of your cognitive health. By playing the games for just a few minutes a day, several times a week, a record of your cognitive health is created. Analytics allow you to understand how your performance varies over time and how it is affected by sleep, diet, and exercise, informing you how to make changes to your lifestyle that can optimise your cognitive health and help delay onset of age-related or illness-related cognitive decline.

BrainWaveBank was founded by Ronan Cunningham, Brian Murphy, Siggı Saevarsson and Urs Streidl in January 2015. It is based in Belfast, Northern Ireland.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://brainwavebank.com">brainwavebank.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | Belfast  |
| Based in:             | 2015   |
| Sector:               | Personalized medicine                                    |
| Total Funding Amount: | £3M  |

# Brand Biology



The company specialises in creating employee engagement and behavioural training programmes with a difference. Using experienced forum theatre actors, it shows employees how to harness the power of their personality in order to create meaningful and engaging connections with customers.

A third of people living with dementia don't feel part of their community and we feel we can all play a part in helping people living with Dementia to continue to receive the service they not only need, but deserve. Over 2.5 million people have become Dementia Friends thanks to the Alzheimer's Society, which has helped them learn a little bit more about what it's like to live with dementia. The events of the company are the logical next step as they use specialist behavioural change methodologies to recreate reality and deliver memorable learning experiences with great results.

This means that attendees can discover practical applications and change their behaviour to identify and support some of the most vulnerable customers in very challenging circumstances. Not only do the events provide a detailed understanding of dementia for all attendees, they also flow naturally on from the Dementia Friends sessions to continue educating colleagues.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://brandbiology.com">brandbiology.com</a> |
| Number of Employees:  | 11-50  |
| Location:             | Bristol  |
| Founded in:           | Undisclosed  |
| Sector:               | Personalized medicine                                  |
| Total Funding Amount: | Undisclosed  |

# Breezie



Breezie

Breezie is the easiest way to enjoy doing more online. Breezie - the Internet made easy. A personalised, intuitive software that converts Android tablets into a simplified experience, and removes clutter and jargon from popular applications and services (Facebook, Google, Skype etc). They are an award-winning London-based start-up aiming to use cutting edge technology to help older adults access the social, commercial and health benefits of being online. Breezie currently sells in the UK and parts of Europe, and recently launched in the US.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://breezie.com">breezie.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | London                                       |
| Based in:             | 2011   |
| Sector:               | Personalized medicine                        |
| Total Funding Amount: | \$7.6M                                       |

# BuddyHub



BuddyHub is a Social Enterprise creating new friendships for older people to help them live well as they age particularly by alleviating and preventing loneliness and isolation through creating meaningful community connections.

BuddyHub creates meaningful new friendships for lonely older adults.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://buddyhub.co.uk">buddyhub.co.uk</a> |
| Number of Employees:  | 5-10   |
| Location:             | London   |
| Founded in:           | Undisclosed  |
| Sector:               | AgeTech  |
| Total Funding Amount: | £188K  |



# C4X Discovery

C4X Discovery aims to become the world's most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates. The Company has two proprietary and synergistic software platforms "Taxonomy3®" and "Conformetrix" that provide a significant competitive advantage when combined with an experienced management team. "Taxonomy3®" is a human genetics analysis platform that utilises a unique mathematical approach to discovery and validation of drug targets for the treatment of a variety of diseases. "Conformetrix" determines the 3D shape of drug molecules from experimental in vitro data that enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas. C4XD's drug discovery engine was further strengthened by the acquisition of technologies from Molplex Ltd, in 2016, which included a software-based system which combines chemoinformatics, computational chemistry and artificial intelligence to optimise the drug discovery process. We have a hybrid business model of wholly-owned programmes and partnerships with pharma, biotech and academics.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://c4xdiscovery.com">c4xdiscovery.com</a> |
| Number of Employees:  | Undisclosed  |
| Founded in:           | Manchester   |
| Based in:             | 2007   |
| Sector:               | Personalized medicine                                  |
| Total Funding Amount: | £5M  |

# Cambridge Biolabs



Millions of people all around the world use ineffective or unsuitable cosmetics every day because the off-the-shelf products currently available on the global cosmetic market do not correspond to the complex set of needs of every individual. This leads to inadvertent negligence and wrong choices due to lack of optimal solution. Skin condition deterioration ensues.

To overcome this we are developing Personal Cosmetic System consisting of more possible personalised formulations than people on Earth. After individual skin diagnosis aided by advanced software and hardware the optimal formula is worked out and created uniquely for the patient in question.

Our formulations are designed to deliver. Each personalised formula boasts a large number of active ingredients (20-40) thus providing unprecedented level of skin health benefits as compared to the 2-3 active ingredients present in most cosmetics currently available on the market.

Thanks to its uniqueness Personal Cosmetic System makes sure that nobody neglects some of his or her skin needs due to lack of choice and knowledge. It also ensures that, based on individual tolerance, unwanted substances be avoided and optimal results achieved.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://cambridge-biolabs.com">cambridge-biolabs.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | Cambridge  |
| Based in:             | 2016   |
| Sector:               | Personalized medicine  |
| Total Funding Amount: | Undisclosed  |

# Cambridge Oncometrix



Cambridge Oncometrix aims to save lives by enabling the early detection of prostate cancer. A condition that is likely to affect 1 in 8 men at some stage of their lives.

Cambridge Oncometrix is developing a non-invasive test that will allow men to check the health of their prostate regularly. A simplified version of the test will be available for home use. A more advanced version will be used in medical institutions.

This test will be capable of accurately detecting aggressive forms of prostate cancer at the early stages of its development.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://camonx.org">camonx.org</a> |
| Number of Employees:  | 1-10                                       |
| Founded in:           | Haverhill                                  |
| Based in:             | 2012                                       |
| Sector:               | Preventive medicine                        |
| Total Funding Amount: | £1.2M                                      |

# CareRooms



We are working with homeowners in your community to provide safe, comfortable CareRooms for convalescence as an alternative to a long hospital stay, to avoid admission into hospital and for short respite breaks. We transform unused spare rooms with our connected healthcare platform, create networks of trained Hosts and put quality of life at the heart of all we do.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://carerooms.com">carerooms.com</a> |
| Number of Employees:  | Undisclosed                                      |
| Founded in:           | Undisclosed                                      |
| Based in:             | Undisclosed                                      |
| Sector:               | Personalized medicine                            |
| Total Funding Amount: | Undisclosed                                      |



# CareZapp



For people who need care at home, whether as a result of ageing, disability or other needs - CareZapp helps connect providers and caring people, providing better insights through smart technologies to enable more effective and positive outcomes.

The CareZapp platform aggregates real-time data from best-of-breed in-home sensors and digital devices, utilised within our applications and analytics to provide meaningful notifications, alerts and better insights on a 24/7 year-round basis.

Our companion apps help to drive engagement within a holistic support network of caring professionals, family, friends, neighbours and community supports for better collaboration, coordination and self-management.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://carezapp.com">carezapp.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | Dublin   |
| Based in:             | 2014   |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed                                    |

# CaringMate



CaringMate delivers technology solutions to drive interoperability, population health management and precision medicine. Its data platform provides end-to-end solution to helps its users manage their patients' data.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://caringmate.com">caringmate.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | London   |
| Based in:             | 2015   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | Undisclosed  |

# Celixir



The team of world-class scientists and biotechnology leadership is devoted to discovering breakthrough medicines that change the standard of medical care for patients. Sir Martin Evans, Nobel Laureate, and Ajan Reginald, former Global Head of Emerging Technologies at Roche, originally founded the company under the name Cell Therapy Ltd (CTL) in 2009 which was rebranded as Celixir in 2016.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://celixir.com">celixir.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | Cardiff                                      |
| Based in:             | 2009   |
| Sector:               | Regenerative medicine                        |
| Total Funding Amount: | \$1.5M                                       |

# Cell Guidance Systems



Cell Guidance Systems commercializes innovative technologies to accelerate and enable stem cell science. We are focussing on (1) the culture of human pluripotent stem cells and (2) the development of highly active, potentiated growth factors. (3) the commercialization of SINEUP technology. SINEUP allows upregulation of protein expression from target genes using an lncRNA transfected into the target cell. Cell Guidance Systems has offices in Cambridge, UK and San Diego, California.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://cellgs.com">cellgs.com</a> |
| Number of Employees:  | 1-10                                       |
| Founded in:           | Cambridge                                  |
| Based in:             | 2010                                       |
| Sector:               | Regenerative medicine                      |
| Total Funding Amount: | £1.5M                                      |

# Cell Medica



Cell Medica is a cell therapy company working on new techniques to cure human diseases based upon a treatment method called cellular immunotherapy. This technique involves harnessing and enhancing the power of the human immune system to fight disease.

Based on a number of academic studies, there is strong evidence that cellular immunotherapy can be used in a safe and effective manner to treat diseases ranging from infections to cancer.

Cell Medica is both an R&D company developing new forms of cell therapies and a cell production/processing company providing clinical-grade cell formulations to hospitals for the treatment of patients.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://cellmedica.co.uk">cellmedica.co.uk</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | London   |
| Based in:             | 2006   |
| Sector:               | Personalized medicine                                  |
| Total Funding Amount: | \$191.8M   |

# Cell and Gene Therapy Catapult



The Cell and Gene Therapy Catapult is a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK as a key part of a global industry. Supported by Innovate UK, our mission is to drive the growth of the industry by helping cell and gene therapy organisations across the world translate early stage research into commercially viable and investable therapies. We are based on the 12th floor of Guy's Hospital in central London, with over 170 cell and gene therapy experts, state-of-the-art development and viral vector laboratories. We have also built a £55m large-scale GMP manufacturing centre to help bring cell and gene therapies to market in the UK and internationally.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://ct.catapult.org.uk">ct.catapult.org.uk</a> |
| Number of Employees:  | 7  |
| Location:             | London   |
| Founded in:           | 2012   |
| Sector:               | Regenerative Medicine                                      |
| Total Funding Amount: | £3M  |

# CellAge



We dream of a world where all people can enjoy their 80s as much as they enjoyed their 20s. A world where people no longer suffer from age-related diseases. A world where we are all given more time to spend with our loved ones.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://cellage.org">cellage.org</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | Glasgow                                      |
| Based in:             | 2016   |
| Sector:               | Personalized medicine                        |
| Total Funding Amount: | Undisclosed                                  |

# CellCap Technologies Limited

The logo for CellCap, consisting of the word "CellCap" in a grey sans-serif font, centered within a grey rectangular box. This box is enclosed in a larger, light blue dashed-line rectangle.

CellCap Technologies Limited was formed in 2012 to exploit their research over the last 2 years in cell separation technologies.

CellCap is using the company's unique approach to cell capture to develop simple consumables for the Life Sciences research sector.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://cell-capture.com">cell-capture.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | Bacup  |
| Based in:             | 2012   |
| Sector:               | Regenerative medicine                                  |
| Total Funding Amount: | £75K   |



# CellCentric

CellCentric

CellCentric's primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.

The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://cellcentric.com">cellcentric.com</a> |
| Number of Employees:  | Undisclosed  |
| Founded in:           | Cambridge  |
| Based in:             | 2003   |
| Sector:               | Regenerative medicine                                |
| Total Funding Amount: | \$32.6M  |

# Celleron Therapeutics



Celleron is building a global oncology company focussed on the clinical development of new and innovative therapies to treat cancer. Celleron's vision is that the future of cancer therapy lies in the ability to match patients to treatments that are tailored to their tumours – effectively selecting the right drug, at the right dose, for the right patient.

Celleron is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. The Company's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://cellerontherapeutics.com">cellerontherapeutics.com</a> |
| Number of Employees:  | Undisclosed  |
| Founded in:           | Abingdon   |
| Based in:             | 2005   |
| Sector:               | Preventive medicine  |
| Total Funding Amount: | \$32.6M  |

# Cellesce



Cellesce Ltd is a biochemical engineering company based in Cardiff in the UK. Cellesce's expertise is in cell expansion which is currently focused on organoids.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://cellesce.com">cellesce.com</a> |
| Number of Employees:  | 1-10  |
| Founded in:           | Malmesbury                                      |
| Based in:             | 2013  |
| Sector:               | Regenerative medicine                           |
| Total Funding Amount: | \$32.6M   |

Launched in November 2016, Cera is a homecare provider that uses digital and artificial intelligence to transform social care. It was co-founded by Dr. Ben Maruthappu and Marek Sacha. Through Cera’s matching algorithm and automated scheduling systems, Cera is able respond to enquiries within the hour, and in 96% of cases start care on the same day when requested. Cera has significantly lower overheads compared to traditional care companies, allowing the company to pay carers up to 50% higher than the industry average, while still offering affordable rates for customers. Cera has received a number of awards including the Most Outstanding Digital Health Innovation of the Year, the LaingBuisson Dementia Care Award, the Best London Home Care Company at the Social Care Awards 2018, Disruptive Leader of the Year and Britain’s Health Startup of the Year. It is a member of the PUBLIC GovStart programme.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://ceracare.co.uk">ceracare.co.uk</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | London   |
| Based in:             | 2016   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | \$21.1M  |

# Choice Care Group



Choice Care Group provides personalized residential support and supported living services for people with learning disabilities, mental health disorders, and complex emotional and behavioral needs. It supports people with a range of complex needs, including Angelman syndrome, autistic spectrum conditions, Asperger's syndrome, bipolar disorders, Cornelia de Lange syndrome, depressions, Down's syndrome, epilepsy, Fragile X syndrome, personality disorders, Prader Willi syndrome, schizophrenia, sensory impairment, Smith-Magenis syndrome, speech and language difficulties, and autism.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://choicecaregroup.com">choicecaregroup.com</a> |
| Number of Employees:  | Undisclosed  |
| Founded in:           | Bracknell  |
| Based in:             | 1992   |
| Sector:               | Personalized medicine  |
| Total Funding Amount: | Undisclosed  |

# Chronos Therapeutics



Chronos Therapeutics' drug development scheme focuses in two main areas:

- Repositioning FDA approved drugs.
- Screening, discovery and development of novel proprietary drug candidates.

## Current Targets

- Diseases of Ageing: Osteoporosis, Cancer and Sarcopenia.
- Neurodegenerative Diseases: Parkinson's Disease, Alzheimer's Disease, ALS and Orphan Synucleopathies.

Chronos Therapeutics' research is successfully advancing from pre-clinical stages of development for age-related disease treatments to clinical development.

Chronos' pioneering drug discovery and development platform the Chronoscreen has enabled the company to quickly gain proprietary positions in the regulation of cellular chronological lifespan.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://chronotherapeutics.com">chronotherapeutics.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | Oxford   |
| Based in:             | 2009   |
| Sector:               | AgeTech  |
| Total Funding Amount: | £8M  |

# Cobra Biologics



Cobra Biologics is a leading international contract manufacturing organisation (CMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply.

Cobra has three GMP approved facilities in Sweden and the UK, each with expertise tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market.

As a trusted provider and a key partner in the drug development and commercialisation process, we take pride in our manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries.

Cobra is a Contract Manufacturing Organisation (CMO) supporting the global life sciences industry in the development and manufacture of monoclonal antibodies (mAb), recombinant proteins, DNA, viruses, phage and cell line derived products and pharmaceuticals for clinical trials and commercial supply.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://cobrabio.com">cobrabio.com</a> |
| Number of Employees:  | 501-1000                                       |
| Founded in:           | Keele  |
| Based in:             | 1992   |
| Sector:               | Regenerative medicine                          |
| Total Funding Amount: | £2.6M  |

# Cognition Kit



Cognition Kit is a platform that will enable doctors, scientists and the public to better understand and manage day-to-day brain health.

Cognition Kit is a platform for measuring real-world cognitive health, enabling researchers to gather better data and clinicians to make better treatment decisions.

Cognition Kit is a collection of cognitive tests that anyone can use on their own smartphone and smartwatch. Each test can be used frequently – up to several times each day – allowing a detailed picture of cognition to be recorded over hours, days, weeks and months.

Cognition Kit is designed to measure cognition in the real world rather than the clinic.

Measuring cognition several times a day, Cognition Kit captures daily fluctuations which would otherwise fall through the net.

Cognition Kit tests are validated against the CANTAB battery - the gold standard in cognitive testing, backed with over 30 years of peer-reviewed evidence.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://cognitionkit.com">cognitionkit.com</a> |
| Number of Employees:  | Undisclosed  |
| Founded in:           | Undisclosed  |
| Based in:             | Undisclosed  |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |



# Collagen Solutions



Collagen Solutions Plc is a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics.

Our capabilities include the provision of native, soluble and powdered collagen formulations and expertise in the development and contract manufacture of collagen components for use as tissue scaffolds and medical devices.

Collagen Solutions' unique offering extends beyond material supply and contract services as our highly skilled staff support customers through various stages of development and regulatory approval, establishing long-term commercial relationships.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://collagensolutions.com">collagensolutions.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | London   |
| Based in:             | 2012   |
| Sector:               | Regenerative medicine  |
| Total Funding Amount: | £18M   |

# Community Lincs



T.E.D. Ageing Better in East Lindsey develops creative ways for older people to be involved in their communities, combating social isolation and loneliness.

T.E.D. is managed by Community Lincs, a charity which aims to:

- reduce rural isolation and vulnerability;
- increase community self-reliance;
- increase the skills and confidence of Lincolnshire people.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://communitylincs.com">communitylincs.com</a> |
| Number of Employees:  | 5-10   |
| Location:             | Sleaford   |
| Founded in:           | Undisclosed  |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |

# Community Men2Men



The Social Enterprise offers (buddying) support to older males (55+) at risk of social isolation, to get them out of the house and take part in fun and interesting activities that appeal to men, and provides help to their families, who can get on with their day with confidence.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://cm2m.co.uk">cm2m.co.uk</a> |
| Number of Employees:  | 5-10                                       |
| Location:             | Daventry                                   |
| Founded in:           | Undisclosed                                |
| Sector:               | AgeTech                                    |
| Total Funding Amount: | Undisclosed                                |

# Complete Care



Complete Care provides high acuity care at home to around 150 individuals with on-going complex clinical healthcare needs. The business employs around 650 personal care assistants (including registered nurses). This acquisition will complement Mitie's existing domiciliary care operations in England and Wales, which are primarily operated through MiHomecare.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://www.completecare.co.uk">completecare.co.uk</a> |
| Number of Employees:  | Undisclosed   |
| Founded in:           | Telford   |
| Based in:             | 1996  |
| Sector:               | AgeTech   |
| Total Funding Amount: | Undisclosed   |

# Connector CIC

The company has designed "Age of Inspiration" events as an amazing and innovative way of engaging with lonely and isolated people. Following on the success of the pilot initiative, it has devised a portfolio of inspirational wellbeing and resilience events aimed at tackling social isolation and now wants to roll-out these events across Lancashire. It uses a variety of methods, including the psychological educational components that teaches the 5 Ways to Wellbeing, using humour, fun and laughter as a mechanism to stay well, connecting individuals to the things that keep them resilient, reduce their isolation and connects them with new and old friends. The company involves a whole host of support agencies to attend these events and have developed a good understanding through networking links with agencies and communities. These events are about connecting people and encouraging them to get involved. Impact is measured through asking individuals to make a promise against the 5 Ways to Wellbeing and they receive a follow-up call in order to gather intelligence which can then be used to produce an impact report.

|                       |                       |
|-----------------------|-----------------------|
| Web site:             | N/A                   |
| Number of Employees:  | 5-10                  |
| Location:             | Undisclosed           |
| Founded in:           | Undisclosed           |
| Sector:               | Preventative Medicine |
| Total Funding Amount: | Undisclosed           |

# Consequential Robotics

Consequential  
ROBOTICS

Consequential Robotics delivers the best of British & international design and engineering to the development of next generation consumer and commercial robots. We aim to create new robot platforms that are inclusively designed, attractive, effective and helpful, with the long-term aim to enhance the quality of human life.

Our emphasis is on understanding how people will use robots in their lives at home, at work, and in shared spaces. Robots will be the eyes, ears and hands of the intelligent house or the smart office, designed to work quietly, safely and unobtrusively; complementing and assisting people not to replacing them. Working closely with our academic and industrial collaborators, Consequential employs the latest artificial intelligence, navigation, mechatronic, human-machine interface, rapid prototyping and flexible manufacturing technologies to create robots that are likeable, reliable, and easy to use.

Their showcase product is MiRo, a friendly, autonomous robo-dog, intended to help keep elderly people safe by reminding them to take medication, suggesting a cup of tea to keep them hydrated, informing them that it's cold outside or contacting assistance if they fall.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://consequentialrobotics.com">consequentialrobotics.com</a> |
| Number of Employees:  | 4   |
| Location:             | Sheffield   |
| Founded in:           | 2016  |
| Sector:               | AgeTech   |
| Total Funding Amount: | Undisclosed   |

# Consulting on Advanced Biologicals



CONSULTING ON ADVANCED BIOLOGICALS (CAB) Ltd is a specialist regulatory consultancy primarily serving the Regenerative Medicine Industry. While their focus is European (EU/EEA) Regulatory Affairs, They have a good understanding of the US system and more importantly understand the differences. Their clients are primarily biopharmaceutical/biotechnology companies but as small independent consultancy They can also offer affordable advice to universities, hospitals, and other non-commercial institutions.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://advbiols.com">advbiols.com</a> |
| Number of Employees:  | Undisclosed                                    |
| Founded in:           | London   |
| Based in:             | Undisclosed                                    |
| Sector:               | Regenerative medicine                          |
| Total Funding Amount: | Undisclosed                                    |

# Cre8 Care



Cre8Care is planning to be a not-for-profit Community Interest Company (CIC). It will attempt to satisfy pressing unmet needs in the health & social care sector through a partner led initiative, innovation in the business model and its open, secure and scalable Intelligent Picture Frame (Platform-as-a-Service).

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://cre8wm.co.uk">cre8wm.co.uk</a> |
| Number of Employees:  | 5-10   |
| Location:             | Worcestershire                                 |
| Founded in:           | Undisclosed                                    |
| Sector:               | Preventative Medicine                          |
| Total Funding Amount: | Undisclosed                                    |



# CRISPR Therapeutics



CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing.

CRISPR Therapeutics' vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://crisprtx.com">crisprtx.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | Cambridge                                      |
| Based in:             | 2013   |
| Sector:               | Regenerative medicine                          |
| Total Funding Amount: | £127M  |

# Ctrl Group

The logo for Ctrl Group, consisting of the words "Ctrl" and "Group" stacked vertically in white text on a pink square background.

317

Ctrl Group is a team of designers, researchers, software developers and healthcare experts who work internationally with healthcare companies and providers who want to use new technology to improve people's health. We create products and services that are effective, engaging and safe.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://ctrl-group.com">ctrl-group.com</a> |
| Number of Employees:  | Undisclosed  |
| Founded in:           | Undisclosed  |
| Based in:             | Undisclosed  |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | Undisclosed  |

# Curam



We at Curam believe that you are the best person to choose your carer or personal assistant – our platform allows you to do this safely, easily and effectively. We have a 12.5% administration charge compared to a typical ISF support provider who will charge over 25% or a traditional agency that will charge up to 50% of the cost of care.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://curamcare.com">curamcare.com</a> |
| Number of Employees:  | Undisclosed                                      |
| Founded in:           | UK   |
| Based in:             | 2018   |
| Sector:               | Personalized medicine                            |
| Total Funding Amount: | Undisclosed                                      |

Cytox have developed a simple genetic based blood test for the assessment of risk and diagnosis of Alzheimer's Disease in the very early stages. Alzheimer's Disease affects over 26 million people world-wide and is a growing condition as people live longer. There is currently no cure for Alzheimer's Disease, but there are large international initiatives underway to find treatments with many drugs in clinical development. Cytox are commercially launching their tests in conjunction with Affymetrix (part of Thermo Fisher Scientific) to support Pharmaceutical and Biotechnology companies developing novel therapeutics.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://cytoxgroup.com">cytoxgroup.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | Manchester   |
| Based in:             | 2004   |
| Sector:               | Preventive medicine                                |
| Total Funding Amount: | £10.3M   |

# Definigen



DefiniGEN was founded in April 2012 to industrialize the OptiDIFF stem cell production platform developed at the University of Cambridge, UK.

The company has world-leading expertise in the area of iPSC production and metabolic disease modelling. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products enabling the development of safer and more effective treatments. In addition the technology platform utilises fully defined and humanized conditions required for the development of regenerative medicine cellular therapies.

DefiniGEN builds on intellectual property and knowledge resident at the University of Cambridge Regenerative Medicine Department at Addenbrooke's Hospital and in addition has in-licensed the Yamanka induced pluripotent stem cell IP portfolio from iPS Academia Japan Inc.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://definigen.com">definigen.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | Cambridge  |
| Based in:             | 2012   |
| Sector:               | Regenerative medicine                            |
| Total Funding Amount: | £5.1M  |

# Destiny Pharma



Destiny Pharma is an innovative pharmaceutical company dedicated to the development of novel antimicrobial products.

Our XF series of compounds have a mechanism of action that is fundamentally different from all existing antibiotics. As the likelihood of resistance developing is very remote, they offer potential advantages in controlling the drug-resistant bacteria that are at the centre of a global healthcare crisis.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://destinypharma.com">destinypharma.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | Brighton   |
| Based in:             | 1996   |
| Sector:               | Preventive medicine                                      |
| Total Funding Amount: | \$37M  |

# Diagnostic Healthcare



Diagnostic Healthcare Ltd, an Altrincham, UK-based diagnostic imaging company. Led by Liat Karni, managing director, and Michael Ringart, chairman, Diagnostic Healthcare has a network of centres and mobile units across the UK providing MRI scans, obstetric ultrasound, bone density scans (DEXA scan), cardiac testing, health screening and reporting services.

The company offers end-to-end integrated solutions, either as mobile services or located within hospitals, GP surgeries or dedicated community sites.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://diagnostichealthcareltd.com">diagnostichealthcareltd.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | Altrincham   |
| Based in:             | 2004   |
| Sector:               | Preventive medicine  |
| Total Funding Amount: | £1M  |

# Digital Care Planning



Digital Care Planning's mission is to help older adults live happier, healthier lives, and avoid unnecessary hospitalisation. It does that by developing tools that help individuals and families take an active role in planning and managing the care they receive. It is the first spin-out company from the Helix Centre - a health care innovation lab backed by Imperial College London and the RCA.

The solution also builds on the evidence base ("A preferable approach to advance care planning may be one that relies not on forms but on carefully structured conversations that explore patients' values." - Scott D. Halpern et al). It's this fusion of evidence-based research and strict human-centred design principles (inherited from the Helix Centre) which set the company apart.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://digitalcareplanning.com">digitalcareplanning.com</a> |
| Number of Employees:  | 5-10  |
| Location:             | London  |
| Founded in:           | Undisclosed   |
| Sector:               | Preventative Medicine   |
| Total Funding Amount: | Undisclosed   |



# Docandu



324

Docandu is an innovative digital health platform that enriches and empowers the patient-doctor relationship. With docandu, patients can connect with the best and trusted doctors, get personalized medical advice and access all their medical files from anywhere, using their smartphone or desktop.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://docandu.com">docandu.com</a> |
| Number of Employees:  | 1-10  |
| Founded in:           | London  |
| Based in:             | 2017  |
| Sector:               | Personalized medicine                         |
| Total Funding Amount: | £60K  |

# DoctorLink



DoctorLink was founded in 2016 to help individuals have a better experience with their GP and at the same time help GP Practices to reduce their growing levels of demand. In 2017 we are launching our first product. It uses a clinically certified Symptom Assessment tool and integrates with your Practices IT system, so we can give personalized healthcare advice for what you need at the moment, and, in case you need to book an appointment with your GP or other NHS Service, we help you with that as well.

We were founded by a team of Healthcare experts and a visionary team that believes technology can empower GP Practices and individuals to do a better job together. We are just getting started and we have a series of developments in the next year which include obtaining a prescription for certain conditions and making referrals to other services (such as physiotherapy) much easier. If your practice is not modernized by using DoctorLink yet, let them know about this new service.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://doctorlink.com">doctorlink.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | London   |
| Based in:             | 2015   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | £20M   |

# Eagle Genomics



Eagle Genomics is an enterprise software solutions company whose products enable the management, orchestration and exploitation of genomics and other life sciences data. We help Life Science companies get the maximum value from their R&D data and we are delivering the information architecture for the genomics era. Our suite of software products radically reduces cost and time to complete research, enabling drastic productivity improvements.

Our architecture translates data sets into data assets, redefining the current paradigm in the industry, enabling the objective measurement of the value of digital assets and providing clarity on “return on information”. Our mix of expertise in biology, bioinformatics, data science and enterprise-class software engineering is unique in the field and has been applied over the last decade to solve our customers’ challenges in areas as diverse as drug development, personal hygiene and plant breeding.

With global customers in the pharmaceuticals, fast moving consumer goods and agri-tech industries we understand the common challenges facing these industries in the handling of ever growing of data and information resources.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://eaglegenomics.com">eaglegenomics.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | Cambridge  |
| Based in:             | 2008   |
| Sector:               | Regenerative medicine                                    |
| Total Funding Amount: | \$7.7M   |

# Earlham Institute



The Earlham Institute (EI) is a research institute focused on exploring living systems by applying computational science and biotechnology to answer ambitious biological questions and generate enabling resources.

The goal of this institute is to be at the forefront of data intensive science in biology, to be a leader in bioinformatics innovation and the application of genome technology and to enable bioscience through dissemination of the data and technology produced in the institute and in collaboration with external scientists worldwide. Project specialisms include wheat and ryegrass, but the wider research carried out includes vertebrate, evolutionary, environment, and regulatory genomics as well as data infrastructure and software development to support the international bioscience community. EI makes its research open access where possible.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://earlham.ac.uk">earlham.ac.uk</a> |
| Number of Employees:  | Undisclosed                                      |
| Founded in:           | Norwich  |
| Based in:             | 2009   |
| Sector:               | Personalized medicine                            |
| Total Funding Amount: | Undisclosed                                      |

# Echo



Echo is a simple, free and secure app that lets you order NHS prescriptions and get medication delivered to your door.

Echo doesn't fix one problem, and isn't a silver bullet. There are many elderly patients who benefit from face-to-face community pharmacy services, particularly when you factor loneliness/isolation. However, for those who struggle with mobility or memory loss, Echo tackles myriad breakpoints in a system that is largely paper-based, fragmented and confusing. They have assembled a team of clinicians, designer and developers to solve a problem Sai and I experience on a personal level. This is what they believe gives them the edge.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://echo.co.uk">echo.co.uk</a> |
| Number of Employees:  | 5-10                                       |
| Location:             | Undisclosed                                |
| Founded in:           | Undisclosed                                |
| Sector:               | Personalised Medicine                      |
| Total Funding Amount: | £8.8M                                      |

# Echo Care



EchoCare develops a non-wearable/non-intrusive, elderly-care, home monitoring system that automatically detects and alerts on emergency and abnormal situations at home. The ECHO system detects various falls, respiration distress and a potential health deterioration. It's based on a unique radar that can cover a standard senior apartment with a single device.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://echocare-tech.com">echocare-tech.com</a> |
| Number of Employees:  | 5-10   |
| Location:             | Undisclosed  |
| Founded in:           | Undisclosed  |
| Sector:               | AgeTech  |
| Total Funding Amount: | \$700K   |



# Edinburgh Molecular Imaging

Edinburgh Molecular Imaging, a Scottish (UK) developer of optical molecular imaging technology. EM Imaging was founded in 2014 by an experienced team of scientists & clinicians. Together they have raised over £15 Million in non-dilutive funding from the Wellcome Trust, EPSRC and MRC to develop a unique range of SMART Agents that enable real-time molecular imaging for the diagnosis of a variety of disease states.

The EM Imaging team has decades of documented success in imaging agent discovery and development with expertise spanning medicinal chemistry, biochemistry and cell biology, along with direct clinical expertise. The team also has significant expertise in the clinical development, approval and reimbursement of molecular imaging agents.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://emimaging.com">emimaging.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | Edinburgh  |
| Based in:             | 2014   |
| Sector:               | Personalized medicine                            |
| Total Funding Amount: | £4M  |

# Elpis BioMed



Elpis Biomed aims to become a leading, global supplier of in vitro cell types for academic research and commercial drug discovery & development purposes. The cells could provide an alternative to the limited supply of primary cells and replace animal studies in other cases. Elpis Biomed's proprietary technology allows rapid generation of highly mature, differentiated cell types at unmatched purity. The process is scalable with the potential to expand product offering with additional cell-types in the neuro-mesoderm focus area. Initial products will be cortical neurons, oligodendrocytes and skeletal muscle cells to be sold to academic research groups and pharma/biotech customers.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://elpis.ltd">elpis.ltd</a> |
| Number of Employees:  | Undisclosed                              |
| Founded in:           | Cambridge                                |
| Based in:             | 2016                                     |
| Sector:               | Personalized medicine                    |
| Total Funding Amount: | £350K                                    |



# Engitix



Engitix is using its proprietary human organ decellularisation technology to develop tissue engineered products for application in regenerative medicine and drug-target research. Engitix' core expertise is treatment and research of liver disease using its proprietary technologies for human extra-cellular matrix (ECM) scaffolds and 3D spheroids for bioartificial liver devices. The scaffold technology is applicable to other organs and disease aetiologies including pancreatic and intestine scaffold products.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://engitix.com">engitix.com</a> |
| Number of Employees:  | Undisclosed                                  |
| Founded in:           | London                                       |
| Based in:             | 2016   |
| Sector:               | Personalized medicine                        |
| Total Funding Amount: | £5M  |

# EnteroBiotix



EnteroBiotix, a privately held Scottish biotechnology company focused on using the body's own microorganisms to prevent and treat disease, has raised £500,000 in an oversubscribed seed round of investment. The financing was led by Equity Gap and supported by the Scottish Investment Bank, the investment arm of Scottish Enterprise.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://enterobiotix.com">enterobiotix.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | Edinburgh  |
| Based in:             | 2017   |
| Sector:               | Preventive medicine                                    |
| Total Funding Amount: | £500K  |

# Epistem Holdings

The logo for Epistem, featuring the word "epistem" in a lowercase, sans-serif font. The "e" is blue, and the rest of the letters are black.

Epistem's specialist contract research services provide valuable support to drug discovery and development pipelines. Epistem's experienced and skilled technical team are dedicated to working with you to provide custom protocols and a personalised service of the highest standard.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://epistemservices.com">epistemservices.com</a> |
| Number of Employees:  | 51-100   |
| Founded in:           | Manchester   |
| Based in:             | 2000   |
| Sector:               | Personalized medicine  |
| Total Funding Amount: | £2.5M  |

eScent® is a highly scalable platform technology that emits microdoses of mood-enhancing aromas at the right time, in the right place, depending on context.

eScent® Contextual Technology for innovations in sensing and dispensing fragrances for digital healthcare, wellbeing, fashion, fragrance, retail applications.

Founded by Dr Jenny Tillotson, Winston Churchill Fellow and Visiting Scholar at the Institute of Biotechnology, University of Cambridge.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://escent.ai">escent.ai</a> |
| Number of Employees:  | Undisclosed                               |
| Founded in:           | Cambridge                                 |
| Based in:             | 2004                                      |
| Sector:               | Preventive medicine                       |
| Total Funding Amount: | Undisclosed                               |

# eTherapeutics



e-Therapeutics plc is a drug discovery and development company. It has developed proprietary computational systems to swiftly and accurately analyse and predict how medicines interact with cells in the body in hopes of optimizing the probability of identifying drug candidates with desirable efficacy and minimal side effects.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://etherapeutics.co.uk">etherapeutics.co.uk</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | Hanborough   |
| Based in:             | 2003   |
| Sector:               | Preventive medicine  |
| Total Funding Amount: | \$66.8M  |

# Evox Therapeutics



Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://evoxtherapeutics.com">evoxtherapeutics.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | Oxford   |
| Based in:             | 2016   |
| Sector:               | AgeTech  |
| Total Funding Amount: | £45.7M   |

# FitnessGenes



FitnessGenes is the first DNA-testing platform of its kind to eliminate guesswork from fitness and nutrition. With a simple DNA test and an intricate analysis of multiple gene variations, their team of genetic scientists reveal specific traits including metabolic tendencies, dietary sensitivities, fat burning capacity, muscle type, recovery time and more. FitnessGenes then prescribes personalized, week-by-week exercise and nutrition programs based on your genetic profile and wellness goals. Featured on The Doctors, in Inc.com, InStyle, The New York Times, Men's Fitness, Shape, SELF and more, FitnessGenes has received notable awards from the UK government and is working with several prestigious academic institutions to further their scientific innovation. Billions of possibilities – only one you.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://fitnessgenes.com">fitnessgenes.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | London   |
| Based in:             | 2013   |
| Sector:               | Preventive medicine                                    |
| Total Funding Amount: | \$6.6M   |

# Freeline Therapeutics



Freeline Therapeutics is a biopharmaceutical company that develops liver directed gene therapies for bleeding disorders and other diseases. Its therapies are based on next-generation proprietary AAV vector platform, with its lead program being a gene therapy to treat haemophilia B.

Freeline Therapeutics was founded in 2015 and is headquartered in London, England.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://freelinetx.com">freelinetx.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | London   |
| Based in:             | 2015   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | \$155.9M   |



# From Generation to Generation



FG2G generates and evaluates innovative local programmes providing solutions to the problems of older and younger people. It does this by bringing them together in local places and spaces in which they can solve their problems by working together.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://fromgeneration2generation.org.uk">fromgeneration2generation.org.uk</a> |
| Number of Employees:  | 5-10   |
| Location:             | Manchester   |
| Founded in:           | Undisclosed  |
| Sector:               | Preventative Medicine  |
| Total Funding Amount: | Undisclosed  |

# Fuss Free Phones



Fuss Free Phones is mobile phone network for older people and those with disabilities, with telephonists to help customers make calls, send texts and look up information on the internet. The unique no nuisance call service protects customers from spam, scam and nuisance calls.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://fussfreephones.com">fussfreephones.com</a> |
| Number of Employees:  | 5-10  |
| Location:             | Undisclosed   |
| Founded in:           | Undisclosed   |
| Sector:               | AgeTech   |
| Total Funding Amount: | Undisclosed   |

# Genedrive Plc



Genedrive plc is a commercial stage medical devices company, targeting opportunities in infectious diseases, biosurveillance, and animal applications. Our Genedrive® system is positioned to offer lower cost, easy to use, point of need or clinic-based molecular diagnostic tests via a 'razor/razor blade' business model across an increasing range of applications. Genedrive® is rapidly reconfigurable for specific assays and is suitable for use outside a traditional hospital setting. The system analyses nucleic acids from fresh or stored samples to provide rapid diagnosis and decision making.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://genedriveplc.com">genedriveplc.com</a> |
| Number of Employees:  | Undisclosed  |
| Founded in:           | Manchester   |
| Based in:             | 2000   |
| Sector:               | Personalized medicine                                  |
| Total Funding Amount: | \$15.6M  |

# GeneFirst



GeneFirst is a molecular diagnostics company working predominantly in the fields of infectious disease, cancer diagnostics and personalized medicine. GeneFirst offers robust easy-to-use, sensitive, and affordable molecular diagnostics technologies and products to researchers, clinicians, and drug companies to enable accurate diagnosis and the delivery of safe and effective medicines.

Its patented technologies allow for simultaneous detection of multiple targets in one reaction.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://genefirst.com">genefirst.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | Abingdon   |
| Based in:             | 2011   |
| Sector:               | Personalized medicine                            |
| Total Funding Amount: | €2.9M  |

# Give & Take Care



Give&TakeCare (G&TC) is a Community Interest Company, based at Brunel University London. The G&TC project is funded by Innovate UK, the government's Innovation Agency for our initial term.

Our aims are:

- To promote person-centred care for older adults (60+) in local communities
- Alleviate issues of loneliness and isolation
- Improve the prospects of care for future generations
- Reduce the ongoing care crisis by expanding the project across the UK

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://giveandtakecare.co.uk">giveandtakecare.co.uk</a> |
| Number of Employees:  | Undisclosed  |
| Founded in:           | UK   |
| Based in:             | 2015   |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |

# Gluecks Bewegungsmusik



Under the motto "Music moves everyone", the GlücksMedienProduktion team develops movement music in the form of sitting dances, sitting gymnastics and sitting sports for people with dementia and people with disabilities, taking into account the principles of sports science. The movement instruction is anchored in the lyrics so that everyone can do our exercises.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://gluecksart.de">gluecksart.de</a> |
| Number of Employees:  | Undisclosed                                      |
| Location:             | Undisclosed                                      |
| Founded in:           | Undisclosed                                      |
| Sector:               | Preventative Medicine                            |
| Total Funding Amount: | Undisclosed                                      |

# Gracewell Healthcare



Gracewell Healthcare is a residential care home company in the United Kingdom.

Gracewell Healthcare Ltd. owns and operates a network of care homes in the United Kingdom. It offers a range of specialist and highly personalized care services in the areas of dementia and respite care, stroke rehabilitation, and nursing and personal care.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://gracewell.co.uk">gracewell.co.uk</a> |
| Number of Employees:  | 501-1000   |
| Founded in:           | Watford  |
| Based in:             | 2010   |
| Sector:               | Personalized medicine                                |
| Total Funding Amount: | £850K  |

# Graphnet Health



Graphnet Health was formed over 20 years ago and is today the UK's no.1 leading supplier of integrated care record software to the NHS and care services. We are part of the System C and Graphnet Care Alliance.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://graphnethealth.com">graphnethealth.com</a> |
| Number of Employees:  | Undisclosed  |
| Founded in:           | UK   |
| Based in:             | Undisclosed  |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |



# Guardian Angel



guardian angel

Guardian Angel is in the process of building an end-of-life marketplace. In an age where technology giants are dramatically changing the entire landscape of our lives, those dealing with death have sat on the sideline. The company aims to positively disrupt the industry, making things like life insurance and funeral plans easier to assemble. In its current form, Guardian Angel helps people cope with one of life's hardest experiences - losing a loved one.

Guardian Angel was inspired by a family tragedy, and its core belief is that being able to address death admin in a straightforward and simple manner will allow the days, weeks and months following the loss of a loved one to be focussed on the truly important things. Once it helps the users with this admin, it will guide them towards getting themselves prepared. Which is where its larger vision sits.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://guardianangel.network">guardianangel.network</a> |
| Number of Employees:  | 5-10   |
| Location:             | Undisclosed  |
| Founded in:           | Undisclosed  |
| Sector:               | Preventative Medicine  |
| Total Funding Amount: | Undisclosed  |

# Guideposts Trust



Guideposts Trust is an existing charity spanning 45 years of expertise in Social Care. It delivers projects that support people facing social exclusion to live a happy, social and independent life, regardless of age, ability or health. By encouraging and enabling people to be a part of, and contribute to their community, we believe that we are reducing loneliness and isolation in the communities.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://guideposts.org.uk">guideposts.org.uk</a> |
| Number of Employees:  | 5-10  |
| Location:             | Witney  |
| Founded in:           | Undisclosed   |
| Sector:               | Preventative Medicine                                     |
| Total Funding Amount: | Undisclosed   |

# GW Pharmaceuticals



GW Pharmaceuticals was founded in 1998 and is listed on both the NASDAQ Global Market (GWPH) and AIM, a market of the London Stock Exchange,. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group's lead programme is the development of a product portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic indications, including Sativex® Oromucosal Spray and Epidiolex® for childhood epilepsy.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://gwpharm.com">gwpharm.com</a> |
| Number of Employees:  | 251-500                                      |
| Founded in:           | Histon                                       |
| Based in:             | 1998   |
| Sector:               | Regenerative medicine                        |
| Total Funding Amount: | \$568.1M                                     |

# Healx

The logo for Healx, featuring the word "healx" in a white, lowercase, sans-serif font on a dark purple square background.

351

Healx is a biotechnology company that develops and offers new therapeutic solutions for patients with rare diseases.

The company offers Rareomics, a tool that helps researchers, charities, and individuals keep up with the latest scientific literature on many rare diseases. It also offers Rarepurposing that helps identify existing drug candidates which can help improve the quality of life of patients with rare diseases.

Healx was founded in 2014 and is based in Cambridge, United Kingdom.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://healx.io">healx.io</a> |
| Number of Employees:  | 1-10                                    |
| Founded in:           | Cambridge                               |
| Based in:             | 2014                                    |
| Sector:               | Personalized medicine                   |
| Total Funding Amount: | \$11.9M                                 |

# HEC Montreal



HEC Montreal is a top-tier research university offering internationally renowned management education and research. The school's mission is to train future managers who contribute to the growth and prosperity of society.

The training program will be based on the self-efficacy theory developed by Albert Bandura at Stanford. Essentially, there are four main sources that can be leveraged to increase confidence and trust: enactive mastery, vicarious experiences, verbal persuasions, and emotional arousal. The latter is particularly important for older individuals as I have shown in a recent study. These sources of self-efficacy will be tailored to the specific requirements of older adults, given reduced fluid intelligence like working memory capacity and improved crystallized intelligence like vocabulary knowledge with age.

|                       |                                    |
|-----------------------|------------------------------------|
| Web site:             | <a href="http://hec.ca">hec.ca</a> |
| Number of Employees:  | Undisclosed                        |
| Location:             | Undisclosed                        |
| Founded in:           | Undisclosed                        |
| Sector:               | Preventative Medicine              |
| Total Funding Amount: | Undisclosed                        |

# Hello Daisy



Too much emphasis is placed on 'doing health' to older people and not enough on creating joy and purpose first, which in turn creates the motivation for self-care and improving personal health and wellbeing'. Our value proposition centres around a physical device that internet enables any TV to allow older people to connect with family and friends in an easy and fear-free manner and in doing so reduces the widening gap of social and digital exclusion. This improved connectivity is the catapult to empowering them to use our platform for self-care especially around falls prevention and other pressing health issues.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://hellodaisy.org">hellodaisy.org</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | London   |
| Based in:             | 2017   |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |

# Heptares Therapeutics



Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets.

The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, Stabilised Receptors), overcoming a major limiting factor to the development of new drugs targeting this group.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://heptares.com">heptares.com</a> |
| Number of Employees:  | 11-50  |
| Founded in:           | 2007   |
| Based in:             | Welwyn Garden City                             |
| Sector:               | Personalized medicine                          |
| Total Funding Amount: | \$61.5M  |

# Heterogeneous



Heterogeneous is a user-centric genetic data marketplace that connects individuals directly to the research world. It act as ethical brokers to facilitate a direct connection between you and research institutions.

The company was founded in 2016 and is headquartered in Cambridge.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://heterogeneous.co.uk">heterogeneous.co.uk</a> |
| Number of Employees:  | 1-10  |
| Based in              | Cambridge   |
| Founded in:           | 2017  |
| Sector:               | Personalized medicine   |
| Total Funding Amount: | £5M   |



# Horizon Discovery



Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company's gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated a catalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12,000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company's own research R&D pipeline.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://horizondiscovery.com">horizondiscovery.com</a> |
| Number of Employees:  | 251-500  |
| Based in              | Cambridge  |
| Founded in:           | 2007   |
| Sector:               | AgeTech  |
| Total Funding Amount: | \$50.3M  |

# HOWZ



Howz analyses electricity usage to understand an elderly person's use of everyday objects, learning what is normal activity and alerting the family when things look out of the ordinary.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://howz.com">howz.com</a> |
| Number of Employees:  | Undisclosed                            |
| Based in              | Manchester                             |
| Founded in:           | Undisclosed                            |
| Sector:               | AgeTech                                |
| Total Funding Amount: | Undisclosed                            |

# hVIVO



hVIVO, a specialty biopharma company with clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases.

hVIVO changed its name from Retroscreen Virology in April 2015. The business is a plc quoted on the AIM London Stock Exchange (ticker 'HVO').

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://hvivo.com">hvivo.com</a> |
| Number of Employees:  | 501-1000                                 |
| Based in              | London                                   |
| Founded in:           | 1988                                     |
| Sector:               | Personalized medicine                    |
| Total Funding Amount: | \$2.6M                                   |

# iamYiam



iamYiam is a preventive health hub that leverages science, genetics, and lifestyle data to create personalized activities and nutrition plans.

iamYiam delivers personal health plans through science-proved preventive actions. The company's mission is to help their clients select and book the best preventive experiences tailored precisely to who they are (all the way down to their genetic makeup) and the goals they want to achieve - powered by Ycloud, their world class technology platform.

The company's proprietary algorithm provides provides personalised health recommendations supported by scientific research and genetic profiling, to help clients select exactly what is best for their health and well-being from a global network of highly recommended practitioners.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://iamyiam.com">iamyiam.com</a> |
| Number of Employees:  | 11-50  |
| Based in              | London                                       |
| Founded in:           | 2017   |
| Sector:               | AgeTech                                      |
| Total Funding Amount: | Undisclosed                                  |



Around the world, patients with unmet medical needs are frequently driven to seek access to medicines outside the clinical trial and commercial setting. IDIS is the leading expert in developing, implementing and managing global Managed Access Programs by which pharmaceutical and biotechnology companies and healthcare providers can respond to the needs of these patients.

IDIS has over 27 years experience of partnering with pharmaceutical and biotechnology companies to create regulatory-compliant, ethical access to medicines for healthcare professionals and their patients with unmet medical needs. Since 1987, IDIS has developed and managed access to thousands of medicines from virtually every therapeutic category, impacting the lives of hundreds of thousands of patients. Around the world, a variety of terms are used to describe these programs including “expanded access”, “named patient”, “ATU”, “compassionate use”, and “early access”.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://idispharma.com">idispharma.com</a> |
| Number of Employees:  | 101-250  |
| Based in              | Weybridge  |
| Founded in:           | 1987   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | Undisclosed  |

# Immune Targeting Systems

IMMUNE TARGETING SYSTEMS

Immune Targeting Systems (ITS) Limited is developing synthetic vaccines for mutating viruses. The Company's enabling T-cell vaccine platform enables it to target highly conserved parts of the virus ("antigens") and direct an T-cell immune response to those cells in the body infected with one of these difficult viruses. The fluoro-peptide vaccine technology then delivers these antigens into the body and promotes robust T-cell immunity without requiring potentially toxic adjuvants which are normally used with vaccines to boost the responses achieved.

The company was founded in late 2003 and is located at the London BioScience Innovation Centre, based in London. In June 2007 the company raised its first major venture capital funding from a syndicate of investors including the Novartis Venture Fund, HealthCap, Truffle Capital & the London Technology Fund. Alongside this investment, the London Development Agency has awarded ITS an Exceptional Development Grant.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://altimmune.com">altimmune.com</a> |
| Number of Employees:  | Undisclosed                                      |
| Based in              | London   |
| Founded in:           | 2003   |
| Sector:               | Personalized medicine                            |
| Total Funding Amount: | \$20.3M  |

# ImmuPharma



ImmuPharma focuses in developing pioneering and novel drugs in specialist therapeutic areas where there is a distinct lack of existing treatments, avoiding primary care (diseases treated by GPs) where many treatments exist. This is consistent with the trends in the pharmaceutical industry.

Since our foundation, our research strategy has been to work closely with the largest fundamental research organisation in Europe, the Centre National de la Recherche Scientifique, (CNRS) in France. This collaboration enables us to access innovative research with substantial embedded value at a relatively low cost, and to work with many leading scientists and doctors. ImmuPharma has exclusive rights to all its intellectual property assets.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://immupharma.org">immupharma.org</a> |
| Number of Employees:  | 1-10   |
| Based in              | Westminster  |
| Founded in:           | 1999   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | \$12.6M  |

# InCommon Living

The logo for InCommon, featuring the word "InCommon" in a red, sans-serif font. The "In" is in a smaller size than "Common". The logo is enclosed in a dashed blue rectangular border.

It brings people together, young and old, to find out what they have in common. The company boosts wellbeing and tackles loneliness amongst older people by taking groups of primary school children into retirement homes to learn from their elders.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://incommonliving.com">incommonliving.com</a> |
| Number of Employees:  | 5-10   |
| Location:             | London   |
| Founded in:           | Undisclosed  |
| Sector:               | Preventative Medicine                                      |
| Total Funding Amount: | Undisclosed  |



# Ingenza



Ingenza was founded in 2002, a spin-out company from the University of Edinburgh that was based on the modification and commercialisation of microbial production technologies aimed at improving yields of unnatural amino acids and amines. Since its inception, Ingenza has remained strongly committed to the continuous development and integration of innovative technologies in its core competencies of molecular biology, gene expression, directed evolution, fermentation and process development.

Ingenza is a world leader in the application of industrial biotechnology and synthetic biology, providing efficient, scalable bioprocesses for the manufacture of chemicals, biologics, pharmaceuticals and biofuels, from sustainable sources.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://ingenza.com">ingenza.com</a> |
| Number of Employees:  | 1-10   |
| Based in              | Dalkeith                                     |
| Founded in:           | 2002   |
| Sector:               | Personalized medicine                        |
| Total Funding Amount: | €50K   |

# IntelliHep



IntelliHep is a spin-out company developing novel drugs for Alzheimers disease and cancer.

The company is untapping the potential of heparin-based therapeutics in biomedical applications including neurodegeneration and cancer. IntelliHep's compounds have further potential applications in inflammation, angiogenesis, wound healing, regenerative medicine and infectious diseases. IntelliHep is exploiting novel technologies and intellectual property to deliver new heparin-based glycans as novel drug leads for specific diseases including Alzheimer's disease and cancer. This is being achieved through in-house R&D and the development of strategic collaborative alliances with external partners.

IntelliHep has developed from work initiated by the Founders at the Universities of Birmingham and Liverpool, and is currently based in the MerseyBio incubator at Liverpool University.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://intellihep.com">intellihep.com</a> |
| Number of Employees:  | Undisclosed  |
| Based in              | Liverpool  |
| Founded in:           | Undisclosed  |
| Sector:               | Regenerative medicine                              |
| Total Funding Amount: | Undisclosed  |

# Invizius



Invizius is developing treatments to help hemodialysis patients live longer, feel better, and suffer fewer cardiovascular complications.

“Despite significant improvements in the quality and efficacy of hemodialysis therapy in recent years, cardiovascular disease (CVD) remains the leading cause of death for dialysis patients. Today, almost half of all dialysis patients die from cardiovascular complications, and life expectancy on dialysis is just one-third of normal. With its proprietary H-Guard™ technology, Invizius is addressing the side effects of hemodialysis to help patients feel better, and suffer fewer cardiovascular complications.”

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://invizius.com">invizius.com</a> |
| Number of Employees:  | Undisclosed                                    |
| Based in              | Edinburgh                                      |
| Founded in:           | 2017   |
| Sector:               | Preventive medicine                            |
| Total Funding Amount: | £1.1M  |

# Jellagen



Jellagen Pty Ltd is a Med-Tech company offering high grade native collagen sourced from jellyfish. Our jellyfish collagen is applicable for tissue engineering, regenerative medicine, stem cell research and a wide variety of cell culture application. We currently supply native collagen for cell culture research supplied in solution or powder.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://jellagen.co.uk">jellagen.co.uk</a> |
| Number of Employees:  | 1-10   |
| Based in              | Pembroke Dock                                      |
| Founded in:           | 2013   |
| Sector:               | Regenerative medicine                              |
| Total Funding Amount: | £5.7M  |

# Kafoodle



Kafoodle Creating or consuming, know your food, inside & out. Striving for food transparency in hospitality & healthcare.

Kafoodle can tell you exactly what you're eating whenever you're eating out - giving you the freedom and confidence to enjoy the foods you love.

Kafoodle Kitchen creates a closer relationship between your kitchen, front of house and customers. You can manage recipes, easily navigate EU regulations, and empower your employees.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://kafoodle.com">kafoodle.com</a> |
| Number of Employees:  | 11-50   |
| Based in              | London  |
| Founded in:           | 2014  |
| Sector:               | Personalized medicine                           |
| Total Funding Amount: | Undisclosed                                     |

# Kalgera



Kalgera is an award winning concept for a digital personal finance manager tailored to the needs of older people.

Every year 5 million older people in the UK fall victim to scams and this forms a large portion of the £38 billion lost each year in the UK to fraud. Kalgera means "good old-age" in Ancient Greek and we want to change this situation and are on a mission to safeguard older people and help them limit financial losses. Kalgera will use Open Banking regulation (also known as Open APIs) and cognitive neurology research to analyse past and present financial behaviour across all financial institutions. Kalgera then uses that data to detect and alert older people and their loved ones to unusual activity so action can be taken to prevent recurrent scams.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://kalgera.com">kalgera.com</a> |
| Number of Employees:  | 1-10   |
| Based in              | Undisclosed                                  |
| Founded in:           | 2016   |
| Sector:               | AgeTech                                      |
| Total Funding Amount: | Undisclosed                                  |

# Kareinn



Kareinn is a care planning and daily record system and so much more.

Kareinn helps you utilise technology to ease the burden of evidencing best practice care to the regulators, retain high quality staff and shift the focus from staying up to date to staying ahead of the curve. We have designed our system to capitalize on the data you already gather to support you and your residents with timely insights.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://kareinn.com">kareinn.com</a> |
| Number of Employees:  | Undisclosed                                  |
| Based in              | Undisclosed                                  |
| Founded in:           | 2015   |
| Sector:               | AgeTech                                      |
| Total Funding Amount: | Undisclosed                                  |

# Kemuri



Kemuri K-Sockets are designed for the kitchens of people who reject wearables, don't accept changes to their established routines and are beginning to decline in their activities of daily living. Machine learning automatically recognises patterns of movement, eating and drinking before checking every hour for significant changes. After detecting many changes, Kemuri sends alerts to 24/7 alarm response centres, family members or carers. They then take action, depending on the underlying reason for the alert.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://kemurisense.com">kemurisense.com</a> |
| Number of Employees:  | Undisclosed  |
| Based in              | Undisclosed  |
| Founded in:           | Undisclosed  |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |



# Kintell LTD



Kintell is a startup founded on the belief that technology can support elderly living and prolong independence. By improving confidence and giving seniors the opportunity to form healthier habits, we have created a device which can provide peace of mind to users and their families.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://kintellhome.com">kintellhome.com</a> |
| Number of Employees:  | 5-10   |
| Location:             | Cambridge  |
| Founded in:           | Undisclosed  |
| Sector:               | Preventative Medicine                                |
| Total Funding Amount: | Undisclosed  |

# Kraydel



Kraydel is a small, plug and play device enabling the elderly to age safely at home. Packed with sensors, it utilises machine learning to provide 24 hour cover and alerts.

Kraydel is the wellness partner for the elderly, reducing loneliness, isolation and enabling safe, independent living.

It is a technology-based service utilising and operating through the largest screen in the home, the TV. We use technologies such as cloud computing, the Internet-of-Things, machine learning and low cost processors. Kraydel can provide connectivity with friends, family and health professionals, monitor health and promote wellness.

Kraydel wraps health & care services around the individual, in their own home, and we have a significant role to play in rebalancing the system towards prevention and enabling elderly people to live longer and live better in their own homes.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://kraydel.com">kraydel.com</a> |
| Number of Employees:  | Undisclosed                                  |
| Based in              | Belfast                                      |
| Founded in:           | Undisclosed                                  |
| Sector:               | AgeTech                                      |
| Total Funding Amount: | £1.2M  |

# Lab21



Lab21 is a rapidly growing healthcare diagnostics business. The company’s vision is of providing personalised diagnostic testing for disease identification, disease predisposition and personalised medicine to protect people from the health problems of tomorrow. We believe that ‘prevention is better than cure’ and aim to provide information that helps to protect people from their health problems of tomorrow. Lab 21 Clinical Laboratory supports healthcare providers and the pharmaceutical and biotechnology industries with technically advanced testing services from its accredited facilities in Cambridge, UK.

The Lab 21 team’s experience and know-how is coupled with a rapidly growing portfolio of molecular and viral diagnostics, plus next generation sequencing, pharmacogenetic and patient profiling tests, which all use cutting-edge technology. This unique combination adds value to pharmaceutical, diagnostic and biotech partners – and directly to clinicians or healthcare providers as they treat and monitor their patients. As we move towards truly personalised healthcare, the Lab 21 team contributes today – delivering high-quality information on drugs and patients that provides real clinical insight.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://lab21.com">lab21.com</a> |
| Number of Employees:  | 51-100                                   |
| Founded in:           | Cambridge                                |
| Based in:             | 2005                                     |
| Sector:               | Personalized medicine                    |
| Total Funding Amount: | \$837.8K                                 |

# Leicestershire Partnership Trust



Leicestershire Partnership NHS Trust provides high quality integrated mental health, learning disability and community health services.

The Trust was created in 2002 to provide mental health, learning disability and substance misuse services. In April 2011 it merged with Leicester City and Leicestershire County and Rutland Community Health Services as a result of the national *Transforming Community Services* agenda. This has given great opportunities to join up mental health and physical health care pathways to advance health and wellbeing for the people and communities of Leicester, Leicestershire and Rutland.

It works with family doctors (GPs), local hospitals, social services and other local authority departments such as housing and education. It also works with voluntary organisations and local community groups. Patients and families are at the heart of everything the company does.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://leicspart.nhs.uk">leicspart.nhs.uk</a> |
| Number of Employees:  | 11-50  |
| Location:             | Leicester  |
| Founded in:           | 2002   |
| Sector:               | Personalized medicine                                  |
| Total Funding Amount: | Undisclosed  |

# Levicept




Lab21 is a rapidly growing healthcare diagnostics business. The company's vision is of providing personalised diagnostic testing for disease identification, disease predisposition and personalised medicine to protect people from the health problems of tomorrow. We believe that 'prevention is better than cure' and aim to provide information that helps to protect people from their health problems of tomorrow. Lab 21 Clinical Laboratory supports healthcare providers and the pharmaceutical and biotechnology industries with technically advanced testing services from its accredited facilities in Cambridge, UK.

The Lab 21 team's experience and know-how is coupled with a rapidly growing portfolio of molecular and viral diagnostics, plus next generation sequencing, pharmacogenetic and patient profiling tests, which all use cutting-edge technology. This unique combination adds value to pharmaceutical, diagnostic and biotech partners – and directly to clinicians or healthcare providers as they treat and monitor their patients. As we move towards truly personalised healthcare, the Lab 21 team contributes today – delivering high-quality information on drugs and patients that provides real clinical insight.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://levicept.com">levicept.com</a> |
| Number of Employees:  | 1-10   |
| Founded in:           | Sandwich                                       |
| Based in:             | 2012   |
| Sector:               | Personalized medicine                          |
| Total Funding Amount: | £12.4M   |

# Life's Back-Up



Life's Back- Up is an ambitious boot strapped tech start up. They are developing a SAAS secure platform, memo. memo will allow users to store, access and share all their vital information. Ongoing gap analysis from their data will drive benefit by recognising actions or products that are necessary at various life stages, which will be prompted via nudges to the user.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://lifesbackup.com">lifesbackup.com</a> |
| Number of Employees:  | Undisclosed   |
| Location:             | Undisclosed   |
| Founded in:           | Undisclosed   |
| Sector:               | AgeTech   |
| Total Funding Amount: | Undisclosed   |

# Lifeline 24



Lifeline24 provide personal alarms for the elderly, disabled and frail within the UK. Our Lifeline Alarms are monitored 24/7 and can provide peace of mind for the whole family. Order online or over the phone today.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://lifeline24.co.uk">lifeline24.co.uk</a> |
| Number of Employees:  | Undisclosed  |
| Based in              | Undisclosed  |
| Founded in:           | Undisclosed  |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |

# LifeStage

By changing from life insurance during working years, when consumers are more interested in that protection, to LTC later in life, when that coverage is more relevant, LifeStage provides the financial protection consumers need, when they need and want it most. Because consumers purchase the protection during their working years, they lock in their premiums at younger ages and as such, pay as much as 50% less than if they waited to buy until age 65. For simplicity sake, the benefit levels and premiums are designed to stay the same for both the term life insurance and the LTC coverage, dramatically simplifying the consumer purchase decision. By providing both life and LTC protection in one product, Lifestage provides two benefits helping address the issue of low perceived value for traditional LTC.

|                       |             |
|-----------------------|-------------|
| Web site:             | N/A         |
| Number of Employees:  | 5-10        |
| Location:             | Undisclosed |
| Founded in:           | Undisclosed |
| Sector:               | AgeTech     |
| Total Funding Amount: | Undisclosed |



# LIFNano Therapeutics



LIFNano Therapeutics was founded in 2013 as a spin-out from the University of Cambridge, progressing to a clinical stage Nano-Bio-Med company specifically focused on targeted delivery of the biologic, Leukaemia Inhibitory Factor (LIF).

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://lifnano.com">lifnano.com</a> |
| Number of Employees:  | 1-10   |
| Based in              | Cambridge                                    |
| Founded in:           | 2015   |
| Sector:               | Preventive medicine                          |
| Total Funding Amount: | £1M  |

# LifT BioSciences



LifT BioSciences is a socially-minded Biotech start-up developing a portfolio of potentially life-saving immuno-oncology cell therapies for different solid tumours using its innate immunity platform, known as Leukocyte Infusion Therapy (LifT). LifT BioSciences Ltd was set-up with Prof Zhen Cui of Wake Forest University, a leading pioneer in LIFT, following his discovery of a cancer resistant (SR/CR) mouse that proved to have transferable innate immunity. The goal is to create a Cell Bank with the potential to cure cancer, using Leukocyte Infusion Therapy (LifT).

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://liftbiosciences.com">liftbiosciences.com</a> |
| Number of Employees:  | Undisclosed  |
| Based in              | London   |
| Founded in:           | 2016   |
| Sector:               | Personalized medicine  |
| Total Funding Amount: | £306K  |

# Lydian stream



Lydianstream harnesses the power of our 'music-centre' in a simple and accessible system.

1. They have codified the behaviours that *have* to be demonstrated to achieve high-level teamwork (...and high quality music-making)
2. They use musical sound as the key to experience, practise and reinforce high-functioning group and individual behaviours
3. They aim to increase collective and individual EQ (Emotional Quotient) and demonstrate this through objective measurement

For the last 20 years, this system has been applied in the fields of conflict resolution and the upgrading of team behaviours in groups, organisations and businesses. It is used directly for relieving stress and anxiety and provides a fresh approach to developing and enhancing mindfulness.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://lydianstream.com">lydianstream.com</a> |
| Number of Employees:  | 5-10   |
| Location:             | Undisclosed  |
| Founded in:           | Undisclosed  |
| Sector:               | Preventative Medicine                                  |
| Total Funding Amount: | Undisclosed  |

# Map a Nurse



Map a Nurse will change the paradigm and disrupt the nurse and patient traditional care system for a more tailor-made service. This is the past! Now, let's look at the present, Map a Nurse will send a professional nurse on-demand to your home, to attend to your medical concerns saving you time and frustration of the unknown. Our app will be developed also considering the way of usage from elderly people so with big character and a simple interface but we will provide also a traditional old-fashion telephone help line to put in touch directly the customer with a nurse and can arrange a visit

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://mapanurse.com">mapanurse.com</a> |
| Number of Employees:  | 5-10   |
| Location:             | London   |
| Founded in:           | Undisclosed                                      |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed                                      |

# Memory Tracks



Memory Tracks is a music-care company. Memory Tracks® is a care platform that links music to daily tasks for those living with cognitive impairment such as dementia.

Those living with dementia live with a wide range of daily issues, such as anxiety, disorientation, anger, fear, irritability, depression, and withdrawal. The use of Memory Tracks music can significantly decrease many of these behaviors, and improve the lives of sufferers, family members, and carers.

We have witnessed this impact, and it is very moving and exciting. Memory Tracks goes further: The beneficiaries of Memory Tracks are primarily those who use it; elderly people living in care or living alone, perhaps with dementia or with chronic loneliness. But it also benefits care workers, families and ultimately society as a whole, improving quality of life, health outcomes and potentially lowering care costs by reducing the need for drugs and improving staff retention in care homes.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://memorytracks.co.uk">memorytracks.co.uk</a> |
| Number of Employees:  | 5-10   |
| Location:             | Undisclosed  |
| Founded in:           | Undisclosed  |
| Sector:               | Preventative Medicine                                      |
| Total Funding Amount: | Undisclosed  |

# Memrica



Memrica Prompt is a digital back up memory, which helps people live well with conditions such as early dementia, mild cognitive impairment, strokes or brain injuries.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://memricaprompt.com">memricaprompt.com</a> |
| Number of Employees:  | 1-10   |
| Based in              | Birmingham   |
| Founded in:           | 2013   |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |

# Methuselah Health



Methuselah Health is a drug discovery company founded in 2015 by Index Ventures to study the role of proteome instability in a number of human diseases linked to ageing.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://methuselah-health.com">methuselah-health.com</a> |
| Number of Employees:  | Undisclosed  |
| Based in              | Cambridge  |
| Founded in:           | 2015   |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |

# Michelson Diagnostics



Michelson Diagnostics is the developer and manufacturer of products based on Multi-Beam Optical Coherence Tomography (OCT), the uniquely powerful, innovative optical imaging technology that is capable of imaging living tissue microstructure at  $< 10 \text{ \AA}\mu\text{m}$  resolution, in real time, to depths of 1 mm or more.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://md-ltd.co.uk">md-ltd.co.uk</a> |
| Number of Employees:  | 11-50  |
| Based in              | Orpington                                      |
| Founded in:           | 2006   |
| Sector:               | Preventive medicine                            |
| Total Funding Amount: | \$10.8M  |



# Micrima



Micrima Ltd. spun out from research at the University of Bristol. The Micrima team is developing radio-wave technology for detecting breast cancer. The technology is non-invasive, non-ionising and inexpensive.

The imaging technology has received extensive validation in the laboratory and is now undergoing first human use trials.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://micrima.com">micrima.com</a> |
| Number of Employees:  | 1-10   |
| Based in              | Bristol                                      |
| Founded in:           | 2005   |
| Sector:               | Preventive medicine                          |
| Total Funding Amount: | \$15M  |

# MiiCARE



miiCARE™ is a social enterprise which was set up by a group of professionals with diverse industry backgrounds, ranging from healthcare to technology and product development. The team came together with one objective in mind - To give vulnerable people (both young and not so young) a Healthy, Safe and Happy life by building on emerging IoT (Internet of Things) technologies and advancement in Artificial Intelligence and Machine Learning.

The solution provided by miiCARE™ also falls under the category of 'disruptive technologies' with unprecedented potential of transforming the current care provision model, by empowering individuals to take more control of their own health and well-being.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://miicare.co.uk">miicare.co.uk</a> |
| Number of Employees:  | Undisclosed                                      |
| Based in              | London   |
| Founded in:           | Undisclosed                                      |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed                                      |

# Minatx



Harnessing the innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients' cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver diseases. Our initial product candidate will achieve clinical proof of concept in 2017.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://minatx.com">minatx.com</a> |
| Number of Employees:  | 1-10                                       |
| Based in              | London                                     |
| Founded in:           | 2008                                       |
| Sector:               | Personalized medicine                      |
| Total Funding Amount: | Undisclosed                                |

# Mission Therapeutics



Mission Therapeutics is a specialist pharmaceutical company whose aim is to translate new molecular understandings of human cell biology into drugs that will markedly improve the management of life-threatening diseases, particularly cancer.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://missiontherapeutics.com">missiontherapeutics.com</a> |
| Number of Employees:  | 11-50  |
| Based in              | Cambridge  |
| Founded in:           | 2011   |
| Sector:               | Personalized medicine  |
| Total Funding Amount: | \$127.6M   |

# Molecular Vision



Molecular Vision is an optical detection company that offers a platform technology solution for versatile optical detection in a portable format. It carries an integration of low-cost organic light emitting diodes and organic photodetectors with analytical devices. This enables the realization of hand-held disposable medical diagnostics devices for point-of-care testing. Additional applications for the portable quantitative analytical devices include in-the-field veterinary testing, food and plant testing, environmental monitoring, and homeland security.

Molecular Vision was founded in 2001 and is based in London, United Kingdom.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://molecularvision.co.uk">molecularvision.co.uk</a> |
| Number of Employees:  | 11-50  |
| Based in              | London   |
| Founded in:           | 2001   |
| Sector:               | Personalized medicine  |
| Total Funding Amount: | \$500K   |

# Mologic



Two quirky scientists vowed to make the world a better place. After learning their trades in some of the world's biggest scientific organisations, Paul and Mark Davis (father and son team with a striking resemblance to Pinky and the Brain established Mologic to do as much good as possible in healthcare and education. They want to improve patient care and quality of life, and break new ground in exciting fields of research (unlike Pinky and the Brain who wanted to take over the world).

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://mologic.co.uk">mologic.co.uk</a> |
| Number of Employees:  | 11-50  |
| Based in              | Thurleigh  |
| Founded in:           | 2003   |
| Sector:               | Personalized medicine                            |
| Total Funding Amount: | \$9.4M   |


# Monica Healthcare



Based in the United Kingdom, Monica Healthcare is developing a series of innovative wearable devices that will use wireless technologies to facilitate globally accessible obstetric services in the home and hospital. The patented technology is based on the acquisition of electro-physiological signals that can be passively detected by electrodes positioned on the maternal abdomen.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://monicahealthcare.com">monicahealthcare.com</a> |
| Number of Employees:  | 11-50  |
| Based in              | Nottingham   |
| Founded in:           | 2005   |
| Sector:               | Preventive medicine  |
| Total Funding Amount: | \$5.9M   |

# Morgan Ash (Care Navigator)



MorganAsh is an expert provider of support services for both consumers and the financial services sector. Trusted by some of the UK's best-known brands, it combines bespoke technology with professional healthcare expertise to deliver a unique range of services.

MorganAsh works with a wide range of organisations, including some of the UK's best-known brands – and the majority of the top UK and Eire life insurance companies.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://morganash.com">morganash.com</a> |
| Number of Employees:  | 11-50  |
| Location:             | Runcorn  |
| Founded in:           | Undisclosed                                      |
| Sector:               | Personalized medicine                            |
| Total Funding Amount: | Undisclosed                                      |



# Move It or Lose It



The company specialises in exercise for the over 60s, offering a unique exercise programme called FABS. Its network of FABS trained instructors delivery group exercise classes for all ability levels giving older people the opportunity to exercise, socialise and have fun. The mission is to change the way we age.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://moveitorloseit.co.uk">moveitorloseit.co.uk</a> |
| Number of Employees:  | 11-50  |
| Location:             | Birmingham   |
| Founded in:           | Undisclosed  |
| Sector:               | Personalized medicine  |
| Total Funding Amount: | Undisclosed  |

# Mursla



Based in Cambridge (UK), Mursla is a startup developing a diagnostic device that leverages proprietary nanostructures to significantly improve cancer detection. Our technology has the potential to simplify the whole cycle of cancer management through utilizing a novel, non-invasive procedure called liquid biopsy.

We provide a competitive and differentiated proposal with superior predictive power potential by identifying panels of circulating wild-type and mutant proteins in blood at the point-of-care. Proteins are the key mediators of regulated or unregulated cellular activities in contrast to circulating nucleic acids assessed by Next-Gen Sequencing Technologies.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://mursla.com">mursla.com</a> |
| Number of Employees:  | 1-10                                       |
| Based in              | Cambridge                                  |
| Founded in:           | 2017                                       |
| Sector:               | Preventive medicine                        |
| Total Funding Amount: | \$1M                                       |

# MyCareMatters



MyCareMatters is a social enterprise established to develop and market an online tool to collect and share a person's non-medical needs and preferences, enabling healthcare professionals to deliver dignified and person-centred care when the person is unable to communicate those things for themselves.

It is very simple to implement and the concept has already received excellent feedback from about 100 healthcare professionals. MyCareMatters itself – a method of sharing a person's needs and preferences when they are unable to communicate those things for themselves - is a natural entry point to a conversation about end-of-life wishes and care.

The information remains under the control of the individual or their carer but can be facilitated by any healthcare professional (or by the individual and/or their carer if they wish). This approach utilises a practical, award-winning tool that is starting to gain traction (MyCareMatters is now in use in hospitals in five counties) and gives healthcare professionals the confidence to approach what they currently find to be a difficult conversation at an earlier stage than is currently the case.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://digitalcareplanning.com">digitalcareplanning.com</a> |
| Number of Employees:  | 5-10   |
| Location:             | Horsham  |
| Founded in:           | Undisclosed  |
| Sector:               | Personalised Medicine  |
| Total Funding Amount: | £15K   |

# My Sense



MySense is a digital health analytics platform that ingests data from a number of fixed and wearable IoT Smart devices to understand an individual's pattern of behaviour and biometric responses based on a set of algorithms and personalised parameters.

The MySense platform learns what "being well" is for an individual and using machine learning can understand when there is a decline in an individual's wellbeing. A monitoring dashboard and alert function is provided to ensure when an individual's wellbeing is declining, care can be provided proactively in a timely manner.

Using wearable and fixed Smart devices we monitor stress, activity levels, fall monitoring, heart-rate, hydration, mobility, blood pressure, long term condition monitoring and more. To do this we have built a strong clinical team who work alongside our bio-systems engineering team (responsible for building the mathematical health models).

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://mysense.ai">mysense.ai</a> |
| Number of Employees:  | 11-50                                       |
| Location:             | London                                      |
| Founded in:           | Undisclosed                                 |
| Sector:               | Personalized medicine                       |
| Total Funding Amount: | Undisclosed                                 |

# Nanokick Technologies

The logo for Nanokick Technologies, featuring the word "NANO" in blue and "KICK" in light blue, with "TECHNOLOGIES" in a smaller font below "NANO".

Nanokick Technologies develops a spin-out, focussing on nanovibrational bioreactor technology for bone regeneration from stem cells.

Nanokick Technologies is an emerging spinout from the Universities of Glasgow and West of Scotland. The company's novel process technology utilizes nanoscale vibration as a means of converting adult stem cells into bone building cells (osteoblasts). This presents potential products for academia, drug discovery and even clinical use.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://nanokick.com">nanokick.com</a> |
| Number of Employees:  | Undisclosed                                    |
| Based in              | Glasgow  |
| Founded in:           | Undisclosed                                    |
| Sector:               | Regenerative Medicine                          |
| Total Funding Amount: | Undisclosed                                    |

# NanoTherics

nanoTherics  
limited

NanoTherics gene transfection studies have shown a significant performance enhancement over the best non-viral techniques currently on the market, demonstrating high levels of transfection whilst, importantly, maintaining the viability of the transfected cells. These two key attributes afford a significant competitive advantage over currently available systems.

NanoTherics mission is to position its novel gene transfection technology as the new gold standard for transfection, underpinning the research and development of current and future gene therapy programmes.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://nanotherics.com">nanotherics.com</a> |
| Number of Employees:  | 11-50  |
| Based in              | Stoke-on-trent                                       |
| Founded in:           | 2007   |
| Sector:               | Personalized medicine                                |
| Total Funding Amount: | £1.1M  |

# Nell Natural Elements



Nell is a Healthtech company making people live longer, healthier lives. The start is 100ml nutrition shots; backed by science, bottled fresh and personalised. The future includes actionable insights into your body using genetic analysis and AI driven content to put people back in control and keep them out of hospital.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://nellhealth.com">nellhealth.com</a> |
| Number of Employees:  | Undisclosed  |
| Based in              | London   |
| Founded in:           | 2016   |
| Sector:               | Preventive medicine                                |
| Total Funding Amount: | Undisclosed  |

# NeoPhore



NeoPhore, based in Cambridge, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Cancer neoantigens are known to stimulate the immune system and potentially be a weak spot in a tumour cell's defence mechanisms. The Company's approach targets genetic mechanisms that both clinical and lab studies suggest will promote neoantigen creation and diversity across numerous cancers. Using these insights, the Company aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://neophore.com">neophore.com</a> |
| Number of Employees:  | Undisclosed                                    |
| Based in              | Cambridge                                      |
| Founded in:           | Undisclosed                                    |
| Sector:               | Preventive medicine                            |
| Total Funding Amount: | £3M  |



# NeRRe Therapeutics



NeRRe Therapeutics Ltd. operates as a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists. The company was founded in 2012 and is based in Stevenage, United Kingdom.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://nerretherapeutics.com">nerretherapeutics.com</a> |
| Number of Employees:  | 11-50  |
| Based in              | Undisclosed  |
| Founded in:           | 2012   |
| Sector:               | Personalized medicine  |
| Total Funding Amount: | \$47M  |

# Newcells Biotech



Newcells Biotech are experts in the production of induced pluripotent stem cells (iPSCs) and their differentiation into a wide range of reliable and reproducible cell and tissue types. Their focus is to provide customers engaged in drug discovery, pre-clinical development and disease mechanism investigation, with the best quality cells and services.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://newcellsbiotech.co.uk">newcellsbiotech.co.uk</a> |
| Number of Employees:  | 1-10   |
| Based in              | Newcastle Upon Tyne  |
| Founded in:           | 2015   |
| Sector:               | Regenerative medicine  |
| Total Funding Amount: | £2.2M  |

# Nightstar Therapeutics



Nightstar Ltd. is a U.K. startup company. Gene therapy is the use of a gene to treat disease. The approach could enable treatments for a several rare conditions caused by mutations in a single gene.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://nightstartx.com">nightstartx.com</a> |
| Number of Employees:  | 11-50  |
| Based in              | London   |
| Founded in:           | 2013   |
| Sector:               | Regenerative medicine                                |
| Total Funding Amount: | \$174.6M   |

# Nuclera Nucleics



Nuclera is a next-generation DNA synthesis company creating tailored solutions for the synthetic biology, industrial enzyme engineering, and pharmaceutical industries. Our proprietary enzyme-mediated DNA synthesis platform will enable the rapid and cost-effective production of highly accurate, ultra-long DNA strands. We aim to be the key provider of long-length variant DNA and genome libraries for protein, biological pathway, and ultimately genome-scale engineering.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://nuclera.com">nuclera.com</a> |
| Number of Employees:  | 1-10   |
| Based in              | Cambridge                                    |
| Founded in:           | 2013   |
| Sector:               | Personalized medicine                        |
| Total Funding Amount: | £828K  |

# Open Bionics



They use 3D printing to make their devices customized for each customer and accessible by anyone.

They're developing the perfect medical grade materials to give their hands the right strength and grip and to make them last.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://openbionics.com">openbionics.com</a> |
| Number of Employees:  | 11-50   |
| Based in              | Bristol   |
| Founded in:           | 2014  |
| Sector:               | Personalized medicine                                 |
| Total Funding Amount: | \$2.9M  |

# Open Hand Project



The Open Hand Project is an open source project with the goal of making robotic prosthetic hands more accessible to amputees.

Leading prosthetics can cost up to \$100,000. By using emerging technologies like 3D printing, we can cut that down to under \$1000. That's two orders of magnitude cheaper, and means that these devices can reach a far broader audience.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://openhandproject.org">openhandproject.org</a> |
| Number of Employees:  | Undisclosed  |
| Based in              | Bristol  |
| Founded in:           | 2013   |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |

# Open Inclusion



Open Inclusion helps businesses understand the needs of their broader customer segments as well as their workforce. They do this primarily through asking people with lived experience of access needs. Our UK wide panel of over 350 people, with a range of impairments or just getting older, engage with us through a broad variety of methodologies.

These cover quantitative, qualitative, behavioural and attitudinal research. We also conduct market research and value analysis drawing on our extensive database of nationally representative statistics covering all major age, disability and impairment categories.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://openinclusion.com">openinclusion.com</a> |
| Number of Employees:  | Undisclosed   |
| Based in              | Undisclosed   |
| Founded in:           | Undisclosed   |
| Sector:               | AgeTech   |
| Total Funding Amount: | Undisclosed   |

# Optellum



Optellum develops an imaging biomarker for smart lung cancer detection. Optellum's vision is to redefine cancer care, by enabling every clinician, in every hospital, to manage their patients in the optimal way. They do that by providing end-end IT platform for personalized early diagnosis and therapy, based on the collective experience of thousands of doctors pooled by machine learning applied to vast patient datasets. Their first suite of products targets management of patients at high risk of developing lung cancer – the world's deadliest and commonest cancer – from early diagnosis through to treatment. Optellum comprises a team of award-winning medical imaging software, AI, and clinical experts who met at Oxford's world-renowned computer vision lab.

Between us, they have track records of bringing innovation to market through over 10 start-up companies, resulting already in 5 trade-sales and one IPO. They are backed by an Advisory Board comprising world-leading clinicians and experts in deep learning ; and Oxford's most prominent investors. They are building up their product development team – join their fight against cancer, working together with former software engineers from top technology companies (Amazon, Facebook, Redhat) and veterans of medical imaging startups (e.g. Mirada Solutions – acquired by Siemens).

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://optellum.com">optellum.com</a> |
| Number of Employees:  | 1-10   |
| Based in              | Oxford   |
| Founded in:           | Undisclosed                                    |
| Sector:               | Personalized medicine                          |
| Total Funding Amount: | €50K   |



# Optibiotix Health



OptiBiotix develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://optibiotix.com">optibiotix.com</a> |
| Number of Employees:  | Undisclosed  |
| Based in              | Heslington   |
| Founded in:           | 2012   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | £1.5M  |

# Orca Pharmaceuticals

The logo for Orca Pharmaceuticals, featuring three vertical bars of varying heights to the left of the company name.

Orca Pharmaceuticals, a new biotechnology start-up focused on treating autoimmune diseases.

Funding is from BioMotiv, a Cleveland, Ohio based therapeutics accelerator affiliated with The Harrington Project, and the New York University Innovation Venture Fund.

The company, located in Oxford UK, is based on technology developed by inventors from New York University (NYU) in collaboration with the founders in the United Kingdom.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://orcapharmaceuticals.com">orcapharmaceuticals.com</a> |
| Number of Employees:  | Undisclosed  |
| Location:             | Abingdon   |
| Founded in:           | 2012   |
| Sector:               | Personalized medicine  |
| Total Funding Amount: | \$1.3M   |

# Orchard Therapeutics



Orchard Therapeutics is a biotechnology company incorporated in September 2015 and dedicated to bringing transformative gene therapies to patients with serious and life-threatening orphan diseases. Our programmes will use the potential of ex-vivo autologous haematopoietic stem cell gene therapy to restore normal gene function in severe and life-threatening inherited disorders.

We work in partnership with the world's leading research centres to harness the life-giving potential of gene therapy. Our mission is to translate results from pre-clinical and early clinical research into commercially approved gene therapies for patients around the world.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://orchard-tx.com">orchard-tx.com</a> |
| Number of Employees:  | 1-10   |
| Location:             | London   |
| Founded in:           | 2015   |
| Sector:               | Regenerative medicine                              |
| Total Funding Amount: | \$310.5M   |

# Orthogem



Orthogem develops and manufactures synthetic bone grafts. Its patented Tripore technology platform has enabled the creation of a pipeline of SBG's formulated for a variety of clinical applications, ranging from spinal to oral craniofacial surgery.

Orthogem's products include TriPore Granules, TriPore MPA, and TriPore Blocks. Wei Lo founded it in 2001, with its headquarters in Nottingham in the United Kingdom.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://orthogem.com">orthogem.com</a> |
| Number of Employees:  | 1-10   |
| Location:             | Nottingham                                     |
| Founded in:           | 2000   |
| Sector:               | Regenerative medicine                          |
| Total Funding Amount: | Undisclosed                                    |

# Orthox



Orthox was founded in 2008 by life scientist, Dr Nick Skaer, and knee surgeon, Professor Oliver Kessler, to exploit the potential of silk technology developed at Oxford University by Professor Fritz Vollrath's Oxford Silk Group in the Department of Zoology. Together with Dr David Knight, Professor Vollrath founded Oxford Biomaterials Ltd to develop and exploit the properties of natural silks for medical applications. The technology they developed was spun out through Isis Innovations, into Spinox Ltd. in 2002 which later became Oxford Biomaterials Ltd. in 2004.

As Chief Scientist and then CEO of Oxford Biomaterials, Dr Skaer co-invented and developed the FibroFix:tm: technology platform over the subsequent four years before securing the exclusive licenses from Oxford Biomaterials to exploit FibroFix:tm: in the field of cartilage and bone repair.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://orthox.co.uk">orthox.co.uk</a> |
| Number of Employees:  | Undisclosed                                    |
| Location:             | Oxford   |
| Founded in:           | 2008   |
| Sector:               | Regenerative medicine                          |
| Total Funding Amount: | £2.5M  |

# Osler Diagnostics

The logo for Osler Diagnostics, featuring the word "OSLER" in a bold, sans-serif font. The letter "O" is stylized with a small green leaf-like shape on its left side. The logo is enclosed in a dashed blue rectangular border.

Osler is developing a handheld diagnostic device capable of testing for a vast range of biomarkers, from just a pinprick of blood, in less than 10 minutes, and at the cost of a few dollars. This represents a ground-breaking development of a broad-purpose diagnostic device available for Point-of-Care settings; as such, it will enable testing to be faster, cheaper, easier, and more accessible. The technology is based on years of world-class academic research from the University of Oxford and has been successfully proven in a research lab context.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://oslerdiagnostics.com">oslerdiagnostics.com</a> |
| Number of Employees:  | 11-50   |
| Location:             | Oxford  |
| Founded in:           | 2016  |
| Sector:               | Personalized medicine   |
| Total Funding Amount: | £2M   |

# Owlett



The company is working on a device that can describe anything placed in front of it to help the visually impaired around the house.

Compared to other solutions, this device is designed to be statically placed in the home and used when something is placed in front of it. People who are partially visually impaired can use a number of apps that can help with this issue, such as TapTapSee and BeMyEyes. These rely on the user to have the ability and sightedness to be able to use a smartphone, which cuts off the completely blind. A number of physical devices also exist such as the OrCam, a head mounted device that can read or describe anything placed in front of it.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://theowlett.com">theowlett.com</a> |
| Number of Employees:  | 5-10   |
| Location:             | Undisclosed                                      |
| Founded in:           | Undisclosed                                      |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed                                      |

# Oxford Biodynamics



Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therap.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://oxfordbiodynamics.com">oxfordbiodynamics.com</a> |
| Number of Employees:  | Undisclosed  |
| Location:             | Oxford   |
| Founded in:           | 2007   |
| Sector:               | Personalized medicine  |
| Total Funding Amount: | £9.8M  |



# Oxford Biomedica



Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and manufacture.

Gene therapy is the treatment of disease by delivering therapeutic DNA into a patient's cells. This can be either in vivo or ex vivo, the latter encompassing the field of cell therapy whereby genetically modified cells are put back into the body.

Their pipeline of seven gene and cell therapy therapy products addresses diseases for which there is currently no treatment or that are inadequately treated today, including ocular and central nervous system disorders. Their product candidates have the potential to transform treatment landscapes.

Their strategy is to develop their product candidates to their next value inflection points whilst continuing to build OXB Solutions into a valuable revenue-generating manufacturing and development services business.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://oxfordbiomedica.co.uk">oxfordbiomedica.co.uk</a> |
| Number of Employees:  | 51-100   |
| Location:             | Oxford   |
| Founded in:           | 1995   |
| Sector:               | Regenerative medicine  |
| Total Funding Amount: | £12.3M   |

# Oxford Gene Technology



Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions.

Founded by Professor Sir Edwin Southern, OGT has helped pioneer the molecular medicine revolution by enabling smarter decision making in human healthcare. With customers in over 60 countries worldwide and ambitious expansion plans, OGT has a strong reputation and increasing share in the large and growing genomic medicine market.

OGT is a rapidly growing company with state-of-the-art facilities and over 100 employees based at our head-office in Begbroke, Oxfordshire, or at our Cytocell office in Cambridge, Cambridgeshire. Since its acquisition in 2017, OGT are a subsidiary of the highly successful Sysmex Corporation, currently ranked in the top 10 global in-vitro diagnostic companies.

|                       |                                      |
|-----------------------|--------------------------------------|
| Web site:             | <a href="http://ogt.com">ogt.com</a> |
| Number of Employees:  | 101-250                              |
| Location:             | Bugbrooke                            |
| Founded in:           | 1995                                 |
| Sector:               | Personalized medicine                |
| Total Funding Amount: | Undisclosed                          |

# Oxford Genetics



422

Oxford Genetics Ltd is a UK based biotechnology company specialising in the production of versatile cloning plasmids for research in academic and biotechnology institutions. they also provide custom cloning and DNA synthesis. All of their products are free of intellectual property restrictions.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://oxfordgenetics.com">oxfordgenetics.com</a> |
| Number of Employees:  | 1-10   |
| Location:             | Upper Heyford  |
| Founded in:           | 2011   |
| Sector:               | Personalized medicine                                      |
| Total Funding Amount: | £10.3M   |

# Oxford Immunotec



Oxford Immunotec is a medical diagnostics company developing novel new tests for various diseases based on its innovative, patented T cell measurement technology. The company's first product is a TB test that diagnoses latent TB infection (LTBI) and TB disease. T-SPOTÂ®. TB is an interferon gamma release assay (IGRA) which are designed to replace the century old Mantoux skin test (TST).

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://oxfordimmunotec.com/international">oxfordimmunotec.com/international</a> |
| Number of Employees:  | 501-1000  |
| Location:             | Abingdon  |
| Founded in:           | 2002  |
| Sector:               | Personalized medicine   |
| Total Funding Amount: | \$106.6M  |

# Oxstem



OxStem plans to develop small molecule drugs that can activate repair mechanisms that already exist within the body.

Building on decades of experience in medicinal chemistry, OxStem will design drugs that can programme resident stem and stem-like cells in situ to treat currently untreatable age-related conditions.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://oxstem.co.uk">oxstem.co.uk</a> |
| Number of Employees:  | 1-10   |
| Location:             | Oxford   |
| Founded in:           | 2013   |
| Sector:               | Regenerative medicine                          |
| Total Funding Amount: | £16.9M   |

# Patients Know Best



Patients Know Best is the world's first patient-controlled medical records system. It is a fully secure online tool which enables patients to better organise, manage and control their own health care provision – it also saves the time of physicians through allowing secure, online consultations.

Founded by Dr. Mohammad Al-Ubaydli, a physician, programmer and expert in IT in healthcare, Patients Know Best has won social enterprise awards for its focus on patient care. Patients Know Best's first customers include Great Ormond Street Hospital, St Mark's Hospital, Novartis and NHS South Devon. Patients Know Best integrates fully into the NHS secure network and is available for use by any patient with any clinician anywhere in the world.

Patients Know Best complies fully with UK NHS and data protection requirements as well as the EU data protection act and US HIPAA legislation for dealing with medical data.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://patientsknowbest.com">patientsknowbest.com</a> |
| Number of Employees:  | 101-250  |
| Location:             | Cambridge  |
| Founded in:           | 2008   |
| Sector:               | Personalized medicine  |
| Total Funding Amount: | \$7.9M   |

# Perfectus Biomed



They are a microbiological services provider that provide our clients with a research based approach to microbiological testing, whilst recognising the client's need for a rapid turnaround and a personalised service. We specialise in bespoke assays with a primary focus on biofilm testing.

They appreciate that not all products are appropriate for standard testing assays and therefore we work closely with our clients to develop methods that are suitable for the testing of novel products.

They offer an extremely customer focused service that includes regular feedback, consultancy, method development and report writing. In addition we produce conference abstracts and posters based on the data we produce.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://perfectusbiomed.com">perfectusbiomed.com</a> |
| Number of Employees:  | 1-10   |
| Location:             | Cheshire   |
| Founded in:           | 2012   |
| Sector:               | Preventive medicine  |
| Total Funding Amount: | £300K  |

# PfT Planning

A land use planning consultancy that believes the 'planning system' could and should be used to address and ameliorate the problems and challenges being posed by an ageing society.

The subdivision of dwellings is a continuing phenomenon. However, using the strong demand for custom-building to enable downsizing in place has not been promoted at has not occurred ar scale. The contribution to the housing stock without building on greenfield, green belt or garden land could be substantial. This might be the best way to upgrade the energy efficiency of some of the 20 million sub-standard dwellings. The planning system has not yet acknowledge the multiple benefits of supporting custom-splitting.

|                       |                       |
|-----------------------|-----------------------|
| Web site:             | N/A                   |
| Number of Employees:  | 5-10                  |
| Location:             | Undisclosed           |
| Founded in:           | Undisclosed           |
| Sector:               | Preventative Medicine |
| Total Funding Amount: | Undisclosed           |



# Phico Therapeutics



Phico Therapeutics is developing a unique antibiotic technology to address one of the most urgent challenges facing medicine today – how to destroy multi-drug resistant bacteria, the so-called “superbugs”.

Phico’s patented platform utilises an antibacterial protein, SASP to inactivate bacterial DNA and cause rapid destruction of target bacteria. SASPject™ is a new class of antibiotic which could provide many advantages over conventional antibiotic classes.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://phicotherapeutics.co.uk">phicotherapeutics.co.uk</a> |
| Number of Employees:  | 11-50  |
| Location:             | Cambridge  |
| Founded in:           | 2000   |
| Sector:               | Personalized medicine  |
| Total Funding Amount: | £11M   |

# Phoqus Pharmaceuticals



Phoqus group is a specialty pharmaceutical company, engages in the development and commercialization of drugs that meet unmet medical needs using the electrostatic deposition technology. Its primary product Chronocort is a Phase II clinical trial product used for the treatment of congenital adrenal hyperplasia and Addison's disease. The company's drug delivery platform, Qtrol, which is derived from electrostatic deposition, enables solid oral dosage forms, such as tablets to be coated in a controlled and precise manner that could then be used to modify the way that a drug is released into the body.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://phoqus.eu">phoqus.eu</a> |
| Number of Employees:  | Undisclosed                              |
| Location:             | West Malling                             |
| Founded in:           | 1998                                     |
| Sector:               | Personalized medicine                    |
| Total Funding Amount: | Undisclosed                              |

# PhoreMost

PHOREMOST  
DRUGGING THE UNDRUGGABLE

PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new 'druggable' target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel 'targeted' therapies more efficiently to market and pass these cost savings onto patients.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://phoremmost.com">phoremmost.com</a> |
| Number of Employees:  | 1-10   |
| Location:             | Cambridge  |
| Founded in:           | 2014   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | \$18.8M  |

# Physiomics



Physiomics plc combines systems biology with cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the company's lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical and clinical trials. This optimisation improves the efficacy of combinations and streamlines the drug development process.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://physiomics-plc.com">physiomics-plc.com</a> |
| Number of Employees:  | Undisclosed  |
| Location:             | Oxford   |
| Founded in:           | 2002   |
| Sector:               | Personalized medicine                                      |
| Total Funding Amount: | Undisclosed  |

# Plan Snap



PlanSnap is a platform that gets people together for any kind of social occasion, fast. It gets everyone to agree on the details of plan - who, what, where, when - so it actually happens. Our mission is to make any social plan happen, starting from any communication platform.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://plansnap.com">plansnap.com</a> |
| Number of Employees:  | 5-10  |
| Location:             | London  |
| Founded in:           | Undisclosed                                     |
| Sector:               | AgeTech   |
| Total Funding Amount: | \$594.6K  |

# Plasticell



Plasticell is a privately held biotechnology company using novel cell culture and drug discovery platforms to produce regenerative small molecule drugs.

Plasticell aims to develop drugs by elucidating the biochemical mechanisms that control the proliferation and differentiation of stem cells, the master cells responsible for tissue development and repair.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://plasticell.co.uk">plasticell.co.uk</a> |
| Number of Employees:  | 11-50  |
| Location:             | London   |
| Founded in:           | 2002   |
| Sector:               | Regenerative medicine                                  |
| Total Funding Amount: | £4.2M  |

# PneumaCare



PneumaCare is a Cambridge (UK)-based company providing clinicians with respiratory diagnostic and monitoring equipment using novel 3D imaging technology. The Company's Thora3Di™ product family are revolutionary non-contact respiratory monitoring systems providing richer information on a broader patient population without the need to breathe into, interact with, or contact the apparatus. Non-contact assessments also reduce risk of infection and instrument running costs.

Thora3Di™ is being used in clinics, pre- and post-operative assessments, drug testing, and device development by both public and private health care providers. Further applications of PneumaCare's proprietary Structured Light Plethysmography technology include home care, neonatal, critical care, and rehabilitation applications.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://pneumacare.com">pneumacare.com</a> |
| Number of Employees:  | 11-50  |
| Location:             | Cambridge  |
| Founded in:           | 2008   |
| Sector:               | Preventive medicine                                |
| Total Funding Amount: | £3.4M  |

# Pocket Clinic



Their vision is to improve the life quality of diabetic patients. Moreover, their mission is to find the best solution to combine High-Technology with daily use devices creating accurate and sustainable methods to measure , analyze and control the disease.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://pockethealthlab.com.br/home">pockethealthlab.com.br/home</a> |
| Number of Employees:  | 1-10   |
| Location:             | London   |
| Founded in:           | 2016   |
| Sector:               | Personalized medicine  |
| Total Funding Amount: | \$40K  |



# Precision Dental Laboratories Group



Precision Dental Laboratories Group is one of the dental laboratory groups, manufacturing a full range of dental products.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://precisiondentalstudio.co.uk">precisiondentalstudio.co.uk</a> |
| Number of Employees:  | Undisclosed  |
| Location:             | Thatcham   |
| Founded in:           | 1999   |
| Sector:               | Personalized medicine  |
| Total Funding Amount: | Undisclosed  |

# Precision Medicines



Precision Medicines is dedicated to improving the lives of cancer patients through developing novel targeted medicines.

Precision Medicines is a clinical stage biotechnology company focussed on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.

The development programs are focused on cancer sub types using a precision or personalized medicine approach, whereby therapies are co-developed with companion biomarkers to target the specific drivers of cancers.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://precimed.com">precimed.com</a> |
| Number of Employees:  | Undisclosed                                    |
| Location:             | Alderley Edge                                  |
| Founded in:           | Undisclosed                                    |
| Sector:               | Personalized medicine                          |
| Total Funding Amount: | Undisclosed                                    |

# Premaitha Health



Premaitha Health is a molecular diagnostics company employing next generation DNA analysis technology to develop.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://premaitha.com">premaitha.com</a> |
| Number of Employees:  | 11-50  |
| Location:             | Manchester                                       |
| Founded in:           | 2013   |
| Sector:               | Personalized medicine                            |
| Total Funding Amount: | £7.3M  |

# Prestige Nursing



Prestige Nursing + Care delivers high-quality, personalized home care to seniors across the UK focusing on a private-pay model.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://prestige-nursing.co.uk">prestige-nursing.co.uk</a> |
| Number of Employees:  | 101-250  |
| Location:             | Wallington   |
| Founded in:           | 1945   |
| Sector:               | Personalized medicine  |
| Total Funding Amount: | Undisclosed  |

# Priestman Goode

**PriestmanGoode.**

It is a design consultancy that delivers exceptional brand experiences for a roster of leading international companies.

The Scooter for Life is a range of products to accompany you through your life and develop as your mobility needs evolve.

The Scooter for Life is a special commission for the New Old exhibition at the Design Museum in London, which opens on 12 January 2017. Presented in the exhibition is a full scale prototype designed to provide users with more independence through greater mobility. The exhibition explores the potential for design to enhance the experience of our later lives and how design can help people lead fuller, healthier and more rewarding lives in an ageing society.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://priestmangoode.com">priestmangoode.com</a> |
| Number of Employees:  | 5-10   |
| Location:             | Undisclosed  |
| Founded in:           | Undisclosed  |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |

# Proteome Sciences



Proteome Sciences is a London (UK) and Frankfurt (Germany) based SME with expertise in proteomics and biomarker research. We have discovered and patented a large number of novel protein biomarkers for diagnosis, prognosis and treatment of key human diseases including neurodegenerative disorders, cancer, stroke etc. and provide protein biomarker services to pharmaceutical and diagnostics companies.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://proteomics.com">proteomics.com</a> |
| Number of Employees:  | Undisclosed  |
| Location:             | London   |
| Founded in:           | 1993   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | Undisclosed  |

# Proximagen



Proximagen is a publicly traded neuroscience research company focused on drug development for neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://proximagen.com">proximagen.com</a> |
| Number of Employees:  | 11-50  |
| Location:             | London   |
| Founded in:           | 2003   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | \$96.5M  |

# Psioxus Therapeutics



PsiOxus Therapeutics Ltd develops novel therapeutics for serious diseases with a particular focus upon cancer.


They are an Oxford based development stage biotechnology company with world leading scientists and a highly experienced management team.

Their approach is to combine macromolecular elements including viruses, polymers and other macro-molecules to produce novel patent protected therapeutics.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://psioxus.com">psioxus.com</a> |
| Number of Employees:  | 11-50  |
| Location:             | Billericay                                   |
| Founded in:           | 2006   |
| Sector:               | Regenerative medicine                        |
| Total Funding Amount: | \$87.5M                                      |



# Pzizz - Sleep, Nap, Focus



"I love Pzizz... Best I've used by a mile" - J.K. Rowling

"Let me tell you, if you do have trouble sleeping, try it, because it really works." -His Royal Highness, The Duke of York

"Give Pzizz a try! Love that app and helps me fall asleep or nap on command." -Daniel Weinand, Co-founder of Shopify

Featured in The New York Times, WIRED, Engadget, Gizmodo, Product Hunt, Lifehacker, Mashable, Newsweek, Sports Illustrated and more.

## PRESS MENTIONS:

"...Hibbert credits the app for helping cure his insomnia and diminish his postgame dependence on Ambien." – NBA Star Roy Hibbert speaking to Sports Illustrated.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://pzizz.com">pzizz.com</a> |
| Number of Employees:  | 11-50                                    |
| Location:             | London                                   |
| Founded in:           | 2015                                     |
| Sector:               | Personalized medicine                    |
| Total Funding Amount: | \$500K                                   |

# QuantuMDx Group



QuantuMDx Group is a young and vibrant medical devices company developing hand-held and portable low cost diagnostic & genomic sequencing platforms capable of supporting the delivery of personalised medicine across both developed and developing nations.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://quantumdx.com">quantumdx.com</a> |
| Number of Employees:  | 11-50  |
| Location:             | Newcastle Upon Tyne                              |
| Founded in:           | 2008   |
| Sector:               | Regenerative medicine                            |
| Total Funding Amount: | \$26.3M  |

# Quethera



Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases. Our initial focus is on developing therapies to reduce progressive visual loss in glaucoma and other conditions affecting the optic nerve. Quethera is working alongside world leaders in the glaucoma field to design clinical trials capable of examining the efficacy and safety of novel therapies in patients who lose parts of their visual field at an accelerated rate (fast-progressors). The company has expertise in gene therapeutic design and development sufficient to progress its pipeline through preclinical testing and into clinical development.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://quethera.co.uk">quethera.co.uk</a> |
| Number of Employees:  | Undisclosed  |
| Location:             | Babraham   |
| Founded in:           | 2013   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | Undisclosed  |

# Reassura



Service to help older people avoid fraud and scams. Primarily through instant access to UK based Fraud Advisors via our freephone number.

53% of over 65s have already been victims of a scam. Once scammed on the phone, victims stop answering the phone, internet victims stop using the internet, doorstep victims stop answering the door. They want to help their members to live life to the full and be confident in all these situations. They provide an old fashioned solution, personalized 1:1 phone conversation whenever our members are confronted by a surprise letter, strange text, cold caller on the doorstep, a too good to be true website or investment proposal. Everyone needs a second opinion sometimes and when members ask us they strengthen their independence.

|                       |             |
|-----------------------|-------------|
| Web site:             | N/A         |
| Number of Employees:  | 5-10        |
| Location:             | London      |
| Founded in:           | Undisclosed |
| Sector:               | AgeTech     |
| Total Funding Amount: | Undisclosed |

# Regenerys



Regenerys develops and sells regenerative medicine products in the streams requiring bioprocessing and biostorage. It offers Myskin, a product for the autologous treatment of serious burns and difficult to heal wounds using cultured allogeneic cells from the patient's own skin; and Cryoskin, a medicine for the treatment of burns using autologous cells.

Regenerys also provides Adiposet, a service to facilitate better cosmetic outcomes in breast cancer surgery and other cosmetic procedures by enabling the storage and return of adipose tissue for lipomodellin. In addition, it offers third party bio-processing and bio-storage services through its laboratories.

Regenerys serves NHS and private healthcare providers in the United Kingdom and other parts of Europe. It began operation in 2011, with its headquarters in Cambridge in the United Kingdom.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://regenerys.com">regenerys.com</a> |
| Number of Employees:  | 11-50  |
| Location:             | Portobello                                       |
| Founded in:           | 2011   |
| Sector:               | Regenerative medicine                            |
| Total Funding Amount: | Undisclosed                                      |

# Remarkable Lives



Remarkable Lives is a private social network: a place to celebrate the life stories of older people and share memories with those who matter most.

With its services you can:

- save a lifetime of memories on a personal timeline - your old photos and stories all in one secure place;
- share with the people who matter most - invite family and friends to add their own memories;
- access your Remarkable Lives profile from any web browser - keep the memories alive and tell your life story, together.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://remarkablelives.co.uk">remarkablelives.co.uk</a> |
| Number of Employees:  | 5-10   |
| Location:             | Undisclosed  |
| Founded in:           | Undisclosed  |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |

# ReMe



The Care Act encourages establishing the Life Story of a person, with the aim of facilitating person centred care and enabling providers to build activity and care around the particular wishes, interests and needs of each person. This usually involves pen and paper. ReMe has digitised the process, enabling family to participate and match their profile with automatically generated internet content. The result is a life vibrantly illustrated with bespoke content that grows day by day.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://remindmecare.com">remindmecare.com</a> |
| Number of Employees:  | Undisclosed  |
| Location:             | Undisclosed  |
| Founded in:           | Undisclosed  |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |

# Renalytix AI


 The logo for Renalytix AI, featuring the word "RENALYTIX" in a grey, sans-serif font and "AI" in a red, sans-serif font, all enclosed within a dashed blue rectangular border.

RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care and patient stratification for drug clinical trials.

RenalytixAI's technology platform will draw from distinct sources of patient data, including large electronic health records, predictive blood-based biomarkers and other genomic information for analysis by learning computer algorithms. RenalytixAI intends to build a deep, unique pool of kidney disease-related data for different AI-enabled applications designed to improve predictive capability and clinical utility over time.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://renalytixai.com">renalytixai.com</a> |
| Number of Employees:  | Undisclosed   |
| Location:             | Penarth   |
| Founded in:           | Undisclosed   |
| Sector:               | Personalized medicine                                 |
| Total Funding Amount: | \$29M   |



# ReNeuron Group




ReNeuron Group Plc engages in the research, development, and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications.

It develops stem cell therapies for a range of neurodegenerative diseases and other conditions, including Parkinson's disease, Type 1 diabetes, and diseases of the retina. The company's therapeutic product pipeline includes ReN001, a pre-clinical development stage therapy for disabled stroke patients. Its other therapeutic and non-therapeutic programs in pre-clinical trials comprise ReN002 for diabetes, ReN003 for retinal diseases, ReN004 for Parkinson's disease, and ReN005 for Huntington's disease. ReNeuron Group also develops and markets neural stem cell lines that include ReNcell VM and ReNcell CX.

The company was founded in 1997 and is headquartered in Guildford, the United Kingdom.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://reneuron.com">reneuron.com</a> |
| Number of Employees:  | 11-50  |
| Location:             | Guildford                                      |
| Founded in:           | 1997   |
| Sector:               | Regenerative medicine                          |
| Total Funding Amount: | \$164.3M                                       |

# Rexgenero



REXGENERO

Rexgenero is a leading regenerative medicine company and developer of advanced cell-based therapeutics for the treatment of serious diseases that are poorly treated with existing therapies. They are conducting clinical trials with their cellular therapies with the intention of obtaining marketing authorization in Europe, the United States and other markets. Their treatments draw on an exceptional understanding of the fundamental science of cell therapies. Their current cell therapies have been developed by the Andalusian Health Authority (Servicio Andaluz de Salud) and Andalusian Initiative of Advanced Therapies and they aim to work with them to develop further cell therapies to treat other indications with high unmet medical needs.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://rexgenero.com">rexgenero.com</a> |
| Number of Employees:  | Undisclosed                                      |
| Location:             | London   |
| Founded in:           | Undisclosed                                      |
| Sector:               | Regenerative medicine                            |
| Total Funding Amount: | \$18.3M  |

# Right Angle



At Right Angle Diagnostics, they believe that revealing specific information encoded within the DNA helps to close the genetic information gap between practitioners and patients, bringing them together one step closer to a satisfying, safer and more successful treatment regimen.

Through their platform, they want to move away from the traditional "one-size-fits-all" era into the personalised treatment era. They believe that targeted genetic information can help your medical practitioners find interventions and therapies tailored around your unique genes, so that they precisely match up with what your body needs.

They want to remove the constraints around accessing qualified specialists - that is why they link patients to practitioners online, to provide you with access to quality healthcare from the comfort of your home.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://rightangled.com">rightangled.com</a> |
| Number of Employees:  | Undisclosed  |
| Location:             | London   |
| Founded in:           | Undisclosed  |
| Sector:               | Personalized medicine                                |
| Total Funding Amount: | £866.6K  |

# Rogue Resolutions



Rogue Resolutions, Ltd., a Cardiff, UK-based start up that provides integrated solutions and services allowing non-invasive neurological treatment methods.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://rogue-resolutions.com">rogue-resolutions.com</a> |
| Number of Employees:  | 1-10   |
| Location:             | Cardiff  |
| Founded in:           | 2010   |
| Sector:               | Personalized medicine  |
| Total Funding Amount: | Undisclosed  |

# Roslin Cells



Roslin Cells is the parent company of Roslin Cell Therapies. Based in Edinburgh, UK Roslin Cell Therapies has a wealth of expertise, capabilities and industry recognition in process translation to GMP, development, optimization, scale up and the GMP manufacture of Cell Therapy and Advanced Therapy Medicinal Products (ATMPs).

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://roslincells.com">roslincells.com</a> |
| Number of Employees:  | 11-50  |
| Location:             | Edinburgh  |
| Founded in:           | 2006   |
| Sector:               | Personalized medicine                                |
| Total Funding Amount: | £887K  |

# RowAnalytics Ltd



RowAnalytics is delivering a range of highly innovative data analytics platforms, which power the next generation of precision medicine, IoT and digital health solutions. RowAnalytics' tools and components allow the delivery of fully personalized solutions for scientists, clinicians, carers and patients in a secure, faster and cost effective manner. We focus on delivering analytical tools that are powerful enough to manage huge, complex datasets, and efficient enough to be deployed across PC, wearable, mobile and embedded devices.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://rowanalytics.com">rowanalytics.com</a> |
| Number of Employees:  | Undisclosed  |
| Location:             | Oxford   |
| Founded in:           | 2013   |
| Sector:               | Personalized medicine                                  |
| Total Funding Amount: | Undisclosed  |

# Sage Therapeutics



Sage Therapeutics is dedicated to the health and wellbeing of patients with central nervous system (CNS) disorders. Our mission is to discover, develop and deliver novel medicines for many of today's most debilitating and disabling CNS disorders by leveraging compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://sagerx.com">sagerx.com</a> |
| Number of Employees:  | 11-50                                      |
| Location:             | Cambridge                                  |
| Founded in:           | 2011                                       |
| Sector:               | Regenerative medicine                      |
| Total Funding Amount: | \$438M                                     |

# Scancell



Scancell is developing therapeutic vaccines for the treatment of cancer and infectious diseases based on its ImmunoBody® and Moditope™ technology platforms. Scancell's first cancer vaccine SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://scancell.co.uk">scancell.co.uk</a> |
| Number of Employees:  | 11-50  |
| Location:             | Nottingham   |
| Founded in:           | 1996   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | £5M  |




# Seniors Rock



A specialist "start up", providing intervention tools and techniques in slowing and prevention of dementia and healthy Longevity – giving people back to themselves and being part of the future.

|                       |                       |
|-----------------------|-----------------------|
| Web site:             | N/A                   |
| Number of Employees:  | 5-10                  |
| Location:             | Undisclosed           |
| Founded in:           | Undisclosed           |
| Sector:               | Personalized medicine |
| Total Funding Amount: | Undisclosed           |

# Sensio Air



White Lab is a healthcare analytics company based in London the US and Lebanon. With a focus on respiratory conditions, the company works to develop cutting-edge technology that identifies airborne particles and helps people predict, prevent and manage the unwanted symptoms that come with asthma and allergies.

Co-founded by professor at UCL and industrial designer Cyrille Najjar and PhD in neuroscience Dr. Eve Tamraz; White Lab unveiled Sensio AIR in 2016. A device and mobile application that allows users to monitor their health at the touch of a screen.

Sensio AIR was designed to improve the quality of life for asthma and allergy sufferers everywhere. Using real-time data and locations from across the world, the app uses AI and Machine Learning to define the correlation between user symptoms and environmental factors or allergens in their vicinity.

|                       |                                      |
|-----------------------|--------------------------------------|
| Web site:             | <a href="http://wlab.io">wlab.io</a> |
| Number of Employees:  | 11-50                                |
| Location:             | London                               |
| Founded in:           | 2016                                 |
| Sector:               | Preventive medicine                  |
| Total Funding Amount: | Undisclosed                          |

# Sernova



Sernova Corp., a health sciences company, focuses on the development and commercialization of medical technologies in the United States and Canada. Its proprietary platform technologies include Cell Pouch System, a device providing a natural organ-like environment for therapeutic cells, such as insulin producing islets for diabetics; and Sertolin, a cell-based technology providing an immune-privileged environment for donor cells, reducing or eliminating the need for anti-rejection drugs. The company also focuses to commercialize products for the treatment of Parkinson's, spinal cord injury, and haemophilia diseases. Sernova Corp. is headquartered in London, Canada.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://sernova.com">sernova.com</a> |
| Number of Employees:  | 1-10   |
| Location:             | London                                       |
| Founded in:           | Undisclosed                                  |
| Sector:               | Personalized medicine                        |
| Total Funding Amount: | \$4.3M                                       |

# Service Robotics Ltd



Service Robotics was founded to bring the benefits of robotics to the older adults of the UK. Its first project is GenieConnect® which is a companionship service designed to allow older adults to remain independent for longer in their own homes. The solution is offered purely as a service and consists of a companion robot, a service centre and software designed to promote cognitive retention.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://genieconnect.co.uk">genieconnect.co.uk</a> |
| Number of Employees:  | 5-10   |
| Location:             | Bristol  |
| Founded in:           | Undisclosed  |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |

# Shift8 Limited

The logo for Shift8 Limited, featuring the word "shift8" in a blue, lowercase, sans-serif font, followed by an asterisk. The logo is enclosed in a dashed blue rectangular border.

464

The company is changing the lives of people living with dementia. It does this by introducing proven technology and is devoted to its implementation through training, exceptional service and a community outreach programme encouraging inter-generational activity.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://shift8.co.uk">shift8.co.uk</a> |
| Number of Employees:  | 5-10   |
| Location:             | London   |
| Founded in:           | Undisclosed                                    |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed                                    |

# Sibelius



Sibelius focuses on the need to support healthy ageing and the increasing market demand for branded, scientifically evidenced, clinically proven natural products. Founded in late 2015, from a spinout out of Oxford University, their patented Chronoscreen™ platform brings new, cost-effective tools to respond to these issues, utilising the validated model organism *Caenorhabditis elegans* to rapidly identify natural products that have the potential for beneficial effects on human health. Their platform permits exploration of the molecular basis of activity, and provides the science to support investment in clinical trials. It also allows screening to identify novel ingredients, improved sources and synergistic mixtures.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://sibeliusnaturalproducts.com">sibeliusnaturalproducts.com</a> |
| Number of Employees:  | 11-50  |
| Location:             | Oxford   |
| Founded in:           | 2015   |
| Sector:               | Preventative medicine  |
| Total Funding Amount: | Undisclosed  |

# Sistemic



Sistemic Ltd. provides drug discovery and repositioning services based on its SistemRNA compound-centric drug discovery technology. It offers services to the biotechnology and pharmaceutical sectors relating to the biology of small RNAs, including microRNAs in cancer and other diseases. The company was founded in 2009 and is based in Glasgow, the United Kingdom with an additional office in Boston, Massachusetts.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://sistemic.co.uk">sistemic.co.uk</a> |
| Number of Employees:  | 11-50  |
| Location:             | Glasgow  |
| Founded in:           | 2009   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | \$1M   |

## SkyePharma (Acquired by Vectura)



SkyePharma has been established in 1996 and is a leading speciality drug delivery company with a proven range of oral and inhalation technologies.

SkyePharma strives to deliver a clinical benefit for patients by using its multiple delivery technologies to create enhanced versions of existing pharmaceutical products as well as products incorporating new chemical entities.

Combining established pre-clinical, clinical and regulatory expertise with the capability to formulate and manufacture drugs, both for clinical studies and commercial sale, SkyePharma identifies and develops potential new therapeutic products for out-licensing as well as working with partners to develop their concepts through to marketable products.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://skyepharma.com">skyepharma.com</a> |
| Number of Employees:  | 101-250  |
| Location:             | London   |
| Founded in:           | 1996   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | Undisclosed  |



# SmartTarget



Evidence is mounting rapidly with regards to the patient benefit of a prostate cancer care pathway guided by MR imaging and targeted biopsy. Clinicians at University College London Hospitals have been working over the past five years with researchers in UCL's Centre for Medical Image Computing to develop an image fusion software for transperineal targeting of the prostate. The resulting CE-marked SmartTarget® device is specifically designed to be agnostic to the clinic's MR and ultrasound equipment, intuitive for the user, fast to set up and slipping easily into existing clinical workflows with minimal disruption. Having also benefited from funding by the UK's Department of Health and the Wellcome Trust, we are pleased to offer a system that is affordable for both the public and private healthcare sectors.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://smarttarget.co.uk">smarttarget.co.uk</a> |
| Number of Employees:  | Undisclosed  |
| Location:             | London   |
| Founded in:           | 2015   |
| Sector:               | Personalized medicine                                    |
| Total Funding Amount: | Undisclosed  |

# Society for Later Life Advisers



SOLLA helps people and their families in finding trusted accredited financial advisers who understand financial needs in later life. As a not for profit standards setting organisation, the Society is highly regarded by many trusted third parties and is a natural referral point for those helping others seeking advice at and throughout retirement.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://societyoflaterlifeadvisers.co.uk">societyoflaterlifeadvisers.co.uk</a> |
| Number of Employees:  | 11-50   |
| Location:             | Sittingbourne   |
| Founded in:           | Undisclosed   |
| Sector:               | AgeTech   |
| Total Funding Amount: | Undisclosed   |

# Solentim



Commercial cell line development for biopharmaceutical production is a high value process that is intrinsically expensive and takes a significant amount of time.

Solentim is dedicated to the development of smart tools that shorten the steps in the upstream cell line development workflow and accelerate timelines.

Their products are the Cell Metric™ series for clone screening, growth and stability measurements.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://solentim.com">solentim.com</a> |
| Number of Employees:  | 11-50  |
| Location:             | Wimborne                                       |
| Founded in:           | 2010   |
| Sector:               | Regenerative medicine                          |
| Total Funding Amount: | Undisclosed                                    |

# Sphere Fluidics



Sphere Fluidics develops novel single cell analysis systems for scientists searching for rare and valuable biological variants across research, therapeutic, bioproduction and diagnostic applications. Their flexible technology, innovative products and range of services help you to boost throughput and sensitivity, while reducing costs and saving time.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://spherfluidics.com">spherfluidics.com</a> |
| Number of Employees:  | 11-50   |
| Location:             | Cambridge   |
| Founded in:           | 2010  |
| Sector:               | Personalized medicine                                     |
| Total Funding Amount: | \$15M   |

# StoriiCare



472

StoriiCare is setting the gold standard for person-centred care. Our cloud based software is used by senior living communities, nursing homes and home care agencies, enabling families to connect with their loved ones and care staff to digitally record their care.

Our HQ is in Glasgow, Scotland, with a remote office in San Francisco, California.

To learn more about StoriiCare, visit [www.storiicare.com](http://www.storiicare.com) To look at our job listings, visit <https://angel.co/storiicare>.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://storiicare.com">storiicare.com</a> |
| Number of Employees:  | 11-50  |
| Location:             | Glasgow City                                       |
| Founded in:           | 2014   |
| Sector:               | AgeTech  |
| Total Funding Amount: | £580K  |

# Suisse Life Science Group plc



Suisse Life Science is a biological big data analytics company that has developed a knowledge-discovery platform to extract cause-effect relationships directly from genetic interpretation – and at scale – linking them to lifestyle data from consumer devices in real time to provide actionable recommendations.

The goal is to leverage these capabilities to transform health from an expert-driven field – with poor predictive power and large gaps in its fundamental understanding of human biology – and transforming it into a data-driven predictive science that makes it as easy as possible for individuals of all ages to take a more active role in managing their health.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://suisselifescience.com">suisselifescience.com</a> |
| Number of Employees:  | 11-50  |
| Location:             | London   |
| Founded in:           | 2016   |
| Sector:               | Personalized medicine  |
| Total Funding Amount: | Undisclosed  |

# SwabTech



SwabTech Ltd is a UK registered medical device company that has spun out of the UK NHS to develop, evaluate and commercialise an automatic swab washing device to support the use of Intra-Operative Cell Salvage within operating theatres.

SwabTech are developing an automated Surgical Swab Washer to enhance blood recovery and reuse during high blood loss surgical procedures. SwabTech's patented Surgical Swab-Washer automates a process currently performed by hand, recovering blood from swabs used in the hospital operating theatre. This blood can then be processed and transfused back into the patient, an established procedure used in a wide range of operations associated with high blood loss, and is known to be a cost-effective means to improve clinical outcomes.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://swabtech.co.uk">swabtech.co.uk</a> |
| Number of Employees:  | 1-10   |
| Location:             | Manchester   |
| Founded in:           | 2012   |
| Sector:               | Regenerative medicine                              |
| Total Funding Amount: | £580K  |

# Swift Molecular Diagnostics



Swift Molecular Diagnostics is a molecular diagnostic company that wants to revolutionise the field of diagnostics and make it accessible to everybody and everywhere. They are developing a novel technology for cost-effective, rapid, easy-to-use and highly specific genetic “yes or no” test that can be performed directly by the side of the patient in under 15 minutes. For the first time in history of molecular diagnostic, anyone will be able to use a DNA test regardless of his location, equipment and training.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://swift dx.co.uk">swift dx.co.uk</a> |
| Number of Employees:  | Undisclosed  |
| Location:             | Cambridge  |
| Founded in:           | Undisclosed  |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | Undisclosed  |



# Synpromics Ltd

476



Synpromics develops and commercializes synthetic promoters to control gene expressions and regulations. The company was founded in 2010 and is based in Edinburgh, United Kingdom.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://synpromics.com">synpromics.com</a> |
| Number of Employees:  | 1-10   |
| Location:             | Edinburgh  |
| Founded in:           | 2010   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | £9.2M  |

# TC BioPharm



TC BioPharm's mission is to develop and commercialise innovative cell-based products to treat disease, improving patient health and Quality of Life.

TC BioPharm is a clinical development company with a cell-based product pipeline capable of treating a variety of disorders including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell®, in renal cell carcinoma, non-small cell lung cancer and melanoma patients.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://tcbiopharm.com">tcbiopharm.com</a> |
| Number of Employees:  | 11-50  |
| Location:             | Holytown   |
| Founded in:           | 2013   |
| Sector:               | Personalized medicine                              |
| Total Funding Amount: | \$34M  |

# The Chatty Café Scheme



The company encourages cafes to have a Chatter & Natter table which is where customers can sit if they are happy to talk to other customers. The aims of the scheme are to reduce loneliness and get people talking.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://thechattycafescheme.co.uk">thechattycafescheme.co.uk</a> |
| Number of Employees:  | 5-10   |
| Location:             | London   |
| Founded in:           | Undisclosed  |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |

# Theolytics



479

Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies.

Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies. The company was formed in 2017 to drive the development of a pipeline of novel clinical trial candidates, and is led by a team that combines over 40 years of experience in oncolytic virus development. The company uses an adenovirus platform to develop targeted, self-amplifying therapeutic agents, and aims to deliver innovative cancer care to millions of people in need worldwide.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://theolytics.com">theolytics.com</a> |
| Number of Employees:  | 2-10   |
| Location:             | Oxford   |
| Founded in:           | 2017   |
| Sector:               | Preventive medicine                                |
| Total Funding Amount: | Undisclosed  |

# Tissue Regenix



Tissue Regenix was founded in May 2006, to commercialise innovative technologies in regenerative medicine. The underpinning science was developed over the last decade in the world-leading Institute for Medical and Biological Engineering at the University of Leeds by Professors John Fisher and Eileen Ingham. The research has received in excess of £4 million grant funding to date from UK research councils (EPSRC, BBSRC) and the Children's Heart Surgery Fund.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://tissueregenix.com">tissueregenix.com</a> |
| Number of Employees:  | 51-100   |
| Location:             | York   |
| Founded in:           | 2006   |
| Sector:               | Regenerative medicine                                    |
| Total Funding Amount: | £685K  |

# Toucan



Toucan is an app that lets users share their bank balance status with a trusted friend or carer using a simple traffic light system. The app is currently being developed by Bailey Kursar with support from Santander, following a hackathon win with the concept in March 2018.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://usetoucan.com">usetoucan.com</a> |
| Number of Employees:  | 5-10   |
| Location:             | London   |
| Founded in:           | Undisclosed                                      |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed                                      |

# Touch Bionics



Touch Bionics Inc., is a Livingston, Scotland, UK-based developer of advanced upper-limb prosthetics.

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://touchbionics.com">touchbionics.com</a> |
| Number of Employees:  | 51-100  |
| Location:             | Livingston  |
| Founded in:           | 2005  |
| Sector:               | Personalized medicine                                   |
| Total Funding Amount: | £5.8M   |

# Tunstall Healthcare Group



Tunstall is a leading provider of telecare/telehealth solutions. Operating in more than 30 countries and employing over 1,200 people, Tunstall supports 2.5 million people around the world. Tunstall's philosophy is simple - to protect, support and care for people - by providing healthcare technology and services that enable anyone requiring support and reassurance, such as older people or those with long term needs, to lead an independent life with dignity and reassurance.

Tunstall provides complete and fully-integrated telecare and telehealth solutions for home, assisted living and specialist care environments, hospital communication systems, associated support services, response centre software systems and monitoring services.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://tunstall.co.uk">tunstall.co.uk</a> |
| Number of Employees:  | 1001-5000  |
| Location:             | North Yorkshire                                    |
| Founded in:           | 1957   |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |



# UGO



UGO provides personal assistance to vulnerable people in their daily using a digital platform to connect users to providers. UGO is a caregiver on demand, requests spot, continuously, even just for one hour. It ensures safety to the elder and relax to the family.

|                       |             |
|-----------------------|-------------|
| Web site:             | N/A         |
| Number of Employees:  | 5-10        |
| Location:             | Undisclosed |
| Founded in:           | Undisclosed |
| Sector:               | AgeTech     |
| Total Funding Amount: | Undisclosed |

# Ukactive



Ukactive is the UK’s leading not-for-profit health body for the physical activity sector, with over 3,500 members from activity providers to major consumer brands, training facilities and equipment manufacturers. Members come from across the private, public and third sector and are united by ukactive’s longstanding and uncompromising commitment to getting more people, more active, more often.

Ukactive facilitates big impact partnerships, conceives and drives breakthrough campaigns, conducts critical research and galvanises key stakeholders to develop and deliver key projects that support and champion the physical activity agenda. The organisation’s efforts are centred around supporting a national ambition to “turn the tide of physical inactivity”.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://ukactive.com">ukactive.com</a> |
| Number of Employees:  | 11-50  |
| Location:             | London   |
| Founded in:           | 1991   |
| Sector:               | Personalised Medicine                          |
| Total Funding Amount: | Undisclosed                                    |

# Vaccitech



Vaccitech is a spin-out company from the University of Oxford's Jenner Institute, one of the oldest and most renowned vaccine research centers in the world.

The company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. Viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. The underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. The company's protected chimpanzee adenovirus technology is the best way to generate T-cell responses and thereby generate lasting cell-mediated immunity.

The founders of the company are Professor Adrian Hill (Director of the Jenner Institute) and Professor Sarah Gilbert (Lead in influenza and MERS), who combine their exceptional scientific skills with regulatory and manufacturing experience.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://vaccitech.co.uk">vaccitech.co.uk</a> |
| Number of Employees:  | 11-50  |
| Location:             | Oxford   |
| Founded in:           | Undisclosed  |
| Sector:               | Personalized medicine                                |
| Total Funding Amount: | £30M   |

# ValiRX



Valirx Plc, an investment holding company, engages in the research and development of oncology therapeutics and diagnostics in the United Kingdom. The company principally offers VAL 101 that acts to shut down the Bcl-2 gene, a proto-oncogene. It develops human papilloma virus diagnostic products based on the Nucleosomics, a platform for non-invasive tests for early cancer diagnosis based on epigenetic signal changes associated with malignancy; and HyperGenomics, a platform for differential diagnostic and prognostic tests in cancer, as well as testing for personalized medicine. The company also develops GeneICE compounds, which treat various diseases by acting to shut down harmful genes and prevent their expression. Valirx Plc is based in London, the United Kingdom.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://valirx.com">valirx.com</a> |
| Number of Employees:  | Undisclosed                                |
| Location:             | London                                     |
| Founded in:           | 2000                                       |
| Sector:               | Personalized medicine                      |
| Total Funding Amount: | £800K                                      |

# Verona Pharma



Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://veronapharma.com">veronapharma.com</a> |
| Number of Employees:  | Undisclosed  |
| Location:             | London   |
| Founded in:           | 2005   |
| Sector:               | Personalized medicine                                  |
| Total Funding Amount: | \$77.1M  |

# Vertex Pharmaceuticals



Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://vrtx.com">vrtx.com</a> |
| Number of Employees:  | 1001-5000                              |
| Location:             | Abingdon                               |
| Founded in:           | 1989                                   |
| Sector:               | Regenerative medicine                  |
| Total Funding Amount: | \$600.4M                               |

# Vida



Vida’s mission is to empower. With technology we empower the elderly, they empower their families, and they empower their carers. Their platform enables a circle of care connecting healthcare providers to the elderly. Everything we do is centred around the cared for, their family and their carers.

They have a wide network of qualified, experienced and trusted carers. They only accept the top 10% of applicants who must have a minimum of two years’ experience. Vida carers must pass our strict in-house recruitment and training processes. Behind them sit a team of leading and award winning care managers and care co-ordinators.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://vida.co.uk">vida.co.uk</a> |
| Number of Employees:  | 11-50                                      |
| Location:             | London                                     |
| Founded in:           | 2016                                       |
| Sector:               | Personalized medicine                      |
| Total Funding Amount: | €1M  |

# Videregen



Videregen Limited operates as a regenerative medicine company.

Videregen's goal is to offer the world's first commercially available organ replacement products to address the chronic shortage of organs for transplantation. Formed in 2011 as a spin-out from Northwick Park Institute of Medical Research in London, it uses its proprietary technology to produce biological scaffolds to which a patient's own stem cells are added, creating a bespoke organ replacement.

Initially focused on diseases of the trachea and bowel, Videregen aims to develop the world's first commercially available organ replacements for these conditions, reducing healthcare costs and improving the quality of life for patients.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://videregen.com">videregen.com</a> |
| Number of Employees:  | 11-50  |
| Location:             | Liverpool  |
| Founded in:           | 2011   |
| Sector:               | Regenerative medicine                            |
| Total Funding Amount: | £3.1M  |



# VirionHealth



492

VirionHealth is a biotechnology company developing ground-breaking therapies for respiratory viral infections. Its pioneering DI platform technology aims provide a new class of biological antiviral active across a range of infectious diseases.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://virionhealth.com">virionhealth.com</a> |
| Number of Employees:  | Undisclosed  |
| Location:             | Coventry   |
| Founded in:           | 2017   |
| Sector:               | Personalized medicine                                  |
| Total Funding Amount: | £13M   |

# Virttu Biologics

The logo for Virttu Biologics, featuring the word "VIRTU" in blue and "BIOLOGICS" in green, both in a sans-serif font.

Virttu is a privately held biotechnology company, which has pioneered the development of oncolytic viruses for treating cancer. Virttu Biologics Limited is a wholly-owned subsidiary of TNK Therapeutics, Inc. and part of the group of companies owned by Sorrento Therapeutics, Inc. Virttu has pioneered the development of oncolytic viruses for treating cancer. Although viruses naturally kill the cells they infect, weakened viruses have been used in medicine for centuries as vaccinations against the infectious diseases they cause. Scientists at Virttu have reprogrammed this ability in a common human virus so that it targets and kills only cancer cells (oncolysis), leaving normal cells unharmed.

Additionally, the presence of the tumour-specific viral infection works as a vaccination triggering the patient's own immune system to mount an anti-cancer response – a treatment known as oncolytic immunotherapy. Virttu's lead oncolytic product SEPREHVIR® has been administered to 102 patients (as at 1st March 2017) with ages ranging from 8 to 84 years and with many different types of cancer including brain, melanoma, head and neck cancer, sarcomas, neuroblastoma and mesothelioma. In these patients, SEPREHVIR can be administered by the route most suitable for their disease which includes systemic administration by intravenous infusion, direct intratumoral injection, and loco-regional infusion. Virttu's scientific and technical expertise in oncolytic virotherapy has been established over 15 years of research and development activity carried out both in-house and with leading researchers in oncolytic immunotherapy, resulting in many firsts in the field and 68 publications in peer-reviewed journals.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://virttu.com">virttu.com</a> |
| Number of Employees:  | Undisclosed                                |
| Location:             | Leeds                                      |
| Founded in:           | 1999                                       |
| Sector:               | Personalized medicine                      |
| Total Funding Amount: | Undisclosed                                |

# Walk With Path



Path is developing innovative walking aids for people with mobility issues caused by injury, ageing, and serious diseases such as diabetes, Multiple Sclerosis and Parkinson's Disease. The aim is to reduce the risk of falls, to keep users mobile for longer and increase independence. This has been proven to increase the quality of life for users and reduce direct and indirect costs for health providers. Path products offer the opportunity to increase quality of life and reduce healthcare costs.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://walkwithpath.com">walkwithpath.com</a> |
| Number of Employees:  | 1-10   |
| Location:             | London   |
| Founded in:           | 2014   |
| Sector:               | AgeTech  |
| Total Funding Amount: | Undisclosed  |

# Wellics



Improving people's lives through the seamless interaction with technology and data science is what drives Wellics. Its scope is to make things simple and meaningful to create value. The expertise of Wellics team is a blend of software engineering, data analytics, health services and product innovation. Its activities are supported by an extensive network of wellness and health experts and leverages tens of experience-years both in industry and academia. Wellics products are simple and smart. They provide actionable, personalized insights by integrating data and profiling information through data analytics, mobile applications and a digital marketplace that seamlessly interact to generate value. Wellics serves corporates, researchers, wellness and health experts. Most importantly Wellics serves everyone who takes self-improvement and quality of life seriously and wants a personal digital coach with them at all times. We are tech freaks, data gurus, health experts and wellness aficionados.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://wellics.com">wellics.com</a> |
| Number of Employees:  | 1-10   |
| Location:             | London                                       |
| Founded in:           | 2016   |
| Sector:               | Personalized medicine                        |
| Total Funding Amount: | Undisclosed                                  |

# WideCells Group



WideCells Group is a transformation in cord blood banking and stem cell treatment; making cord blood banking more accessible through insurance coverage, and increasing the availability of cord blood for transplants.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://widecellsgroup.com">widecellsgroup.com</a> |
| Number of Employees:  | 11-50  |
| Location:             | Manchester   |
| Founded in:           | 2012   |
| Sector:               | Personalized medicine                                      |
| Total Funding Amount: | Undisclosed  |

# Wise-Up

Wise-Up<sup>©</sup>

497

The company consists of academics at London South Bank University (LSBU) who have experience in the health needs of a large diversity of people and are qualified health professionals in Occupational Health and in Social Care. LSBU is engaged with solving real problems in the real world, has many KTPs start-up companies and has business translation facilities and expertise.

|                       |                       |
|-----------------------|-----------------------|
| Web site:             | N/A                   |
| Number of Employees:  | 5-10                  |
| Location:             | London                |
| Founded in:           | Undisclosed           |
| Sector:               | Preventative Medicine |
| Total Funding Amount: | Undisclosed           |

# Xenetic Biosciences



Xenetic Biosciences PLC (formerly Lipoxen PLC) Xenetic is a leading UK-based clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics. Their product pipeline includes:

**PolyXen™** is a patent-protected enabling platform technology designed for protein or peptide therapeutics. It uses the natural polymer polysialic acid (PSA) to prolong a drug's circulating half-life and potentially improve other pharmacological properties. PolyXen has been demonstrated in human clinical trials to confer extended half-life to biotherapeutics such as recombinant human erythropoietin and recombinant Factor VIII (rFVIII). **XBIO-101 (sodium cridanimod)**: XBIO-101 is a small-molecule immunomodulator and interferon inducer which, in preliminary studies, has been shown to increase progesterone receptor (PrR) expression in endometrial tissue.

|                       |  |
|-----------------------|--|
| Web site:             | <a href="http://htxeneticbio.com">htxeneticbio.com</a> |
| Number of Employees:  | 11-50  |
| Location:             | London   |
| Founded in:           | 2014   |
| Sector:               | Preventive medicine                                    |
| Total Funding Amount: | \$10M  |

# Zio Health



Zio Health is a healthcare platform allowing its users to know molecular health status. The company develops multi-functional electronic devices for measuring, testing and detecting the molecular composition of chemical and biological substances for the presence, absence, or quantity of target molecules.

Their services include analysis of:

- Home Diagnostics (Blood, Urine, Saliva, Breast-milk)
- Point-of-Care Devices for Healthcare institutions
- Remote Medical Testing
- Water Quality Testing
- Food Quality Testing
- Formula Milk Quality Testing

|                       |   |
|-----------------------|---|
| Web site:             | <a href="https://z.io/health.com">z.io/health.com</a> |
| Number of Employees:  | 11-50   |
| Location:             | London  |
| Founded in:           | Undisclosed   |
| Sector:               | Personalized medicine                                 |
| Total Funding Amount: | Undisclosed   |